Embed Size (px)
Citation preview
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
Appendix 4 lists the answer distribution by Group and data item for each of the cases.
The final answer is highlighted in blue
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 2
Group 1-BrainGroup 1 Brain: Primary Site
Answer N Percent
C718 97 56.7 C711 62 36.3
C719 7 4.1
C700 2 1.2
C710 2 1.2
C716 1 0.6
Total 171 100
Group 1 Brain: Histology Answer N Percent
9440 162 94.7 9445 4 2.3
8440 2 1.2
8000 1 0.6
9133 1 0.6
9400 1 0.6
Total 171 100
Group 1 Brain: Behavior Answer N Percent
3 170 99.4 0 1 0.6
Total 171 100
Group 1 Brain: Tumor Size Clinical Answer N Percent
086 122 71.3 040 24 14
999 8 4.7
036 5 2.9
055 5 2.9
000 1 0.6
004 1 0.6
Answer N Percent
080 1 0.6
094 1 0.6
400 1 0.6
550 1 0.6
860 1 0.6
Total 171 100
Group 1 Brain: Tumor Size Pathologic Answer N Percent
999 164 95.9 086 5 2.9
000 1 0.6
400 1 0.6
Total 171 100
Group 1 Brain: EOD Primary Tumor Answer N Percent
500 130 76 100 29 17
999 7 4.1
700 4 2.3
050 1 0.6
Total 171 100
Group 1 Brain: EOD Regional Nodes Answer N Percent
888 171 100 Total 171 100
Group 1 Brain: EOD Mets Answer N Percent
99 155 90.6 00 10 5.8
98 6 3.5
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 3
Answer N Percent
Total 171 100
Group 1 Brain: SS2018 Answer N Percent
2 125 73.1 1 28 16.4
9 8 4.7
7 7 4.1
8 3 1.8
Total 171 100
Group 1 Brain: Grade Clinical Answer N Percent
4 136 79.5 9 17 9.9
H 16 9.4
1 1 0.6
3 1 0.6
Total 171 100
Group 1 Brain: Grade Pathological Answer N Percent
9 112 65.5 4 57 33.3
1 1 0.6
H 1 0.6
Total 171 100
Group 1 Brain: Grade Post Therapy Answer N Percent
BLANK 134 78.4 9 35 20.5
1 1 0.6
4 1 0.6
Total 171 100
Group 1 Brain: Brain Molecular Markers Answer N Percent
05 138 80.7
99 15 8.8
88 5 2.9
02 4 2.3
01 3 1.8
04 3 1.8
85 3 1.8
Total 171 100
Group 1 Brain: Chromosome 1p Status Answer N Percent
9 155 90.6 0 9 5.3
8 6 3.5
1 1 0.6
Total 171 100
Group 1 Brain: Chromosome 19q Status Answer N Percent
9 158 92.4 8 6 3.5
0 5 2.9
1 2 1.2
Total 171 100
Group 1 Brain: MGMT Answer N Percent
0 138 80.7 9 20 11.7
8 6 3.5
1 4 2.3
3 2 1.2
2 1 0.6
Total 171 100
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 4
Group 1-Breast
Group 1 Breast: Primary Site Answer N Percent
C508 92 55.8 C504 52 31.5
C505 16 9.7
C509 3 1.8
C501 1 0.6
C502 1 0.6
Total 165 100
Group 1 Breast: Histology Answer N Percent
8500 160 97 8521 2 1.2
8140 1 0.6
8520 1 0.6
8550 1 0.6
Total 165 100
Group 1 Breast: Behavior Answer N Percent
3 165 100 Total 165 100
Group 1 Breast: Tumor Size Clinical Answer N Percent
080 72 43.6 038 68 41.2 050 7 4.2
070 7 4.2
084 2 1.2
009 1 0.6
015 1 0.6
020 1 0.6
Answer N Percent
027 1 0.6
028 1 0.6
083 1 0.6
088 1 0.6
380 1 0.6
999 1 0.6
Total 165 100
Group 1 Breast: Tumor Size Pathologic Answer N Percent
999 157 95.2 080 5 3
004 1 0.6
012 1 0.6
380 1 0.6
Total 165 100
Group 1 Breast: EOD Primary Tumor Answer N Percent
100 147 89.1
200 6 3.6
999 5 3
300 4 2.4
000 1 0.6
050 1 0.6
800 1 0.6
Total 165 100
Group 1 Breast: EOD Regional Nodes Answer N Percent
000 150 90.9 070 5 3
150 5 3
999 4 2.4
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 5
Answer N Percent
100 1 0.6
Total 165 100
Group 1 Breast: Regional Nodes Positive Answer N Percent
00 124 75.2 98 29 17.6
99 7 4.2
95 4 2.4
01 1 0.6
Total 165 100
Group 1 Breast: EOD Mets Answer N Percent
00 158 95.8 05 3 1.8
70 2 1.2
10 1 0.6
99 1 0.6
Total 165 100
Group 1 Breast: SS2018 Answer N Percent
1 150 90.9 2 8 4.8
9 3 1.8
0 2 1.2
3 1 0.6
7 1 0.6
Total 165 100
Group 1 Breast: Grade Clinical Answer N Percent
1 150 90.9 9 6 3.6
Answer N Percent
A 4 2.4
2 2 1.2
3 2 1.2
H 1 0.6
Total 165 100
Group 1 Breast: Grade Pathological Answer N Percent
9 143 86.7 1 20 12.1
3 2 1.2
Total 165 100
Group 1 Breast: Grade Post Therapy Answer N Percent
BLANK 97 58.8 9 65 39.4
1 2 1.2
2 1 0.6
Total 165 100
Group 1 Breast: Sentinel Lymph Nodes Examined
Answer N Percent
00 78 47.3 98 41 24.8
01 24 14.5
99 13 7.9
95 9 5.5
Total 165 100
Group 1 Breast: Sentinel Lymph Nodes Positive Answer N Percent
00 96 58.2 98 54 32.7
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 6
Answer N Percent
99 12 7.3
95 2 1.2
03 1 0.6
Total 165 100
Group 1 Breast: ER Summary Answer N Percent
0 160 97 1 3 1.8
9 2 1.2
Total 165 100
Group 1 Breast: ER Percent Positive Answer N Percent
000 142 86.1 XX9 16 9.7
XX7 3 1.8
001 1 0.6
095 1 0.6
R40 1 0.6
XX8 1 0.6
Total 165 100
Group 1 Breast: ER Allred Score Answer N Percent
X9 108 65.5 00 50 30.3
X8 4 2.4
01 2 1.2
08 1 0.6
Total 165 100
Group 1 Breast: PR Summary Answer N Percent
0 159 96.4 9 4 2.4
1 2 1.2
Total 165 100
Group 1 Breast: PR Percent Positive Answer N Percent
000 138 83.6 XX9 22 13.3
XX8 2 1.2
001 1 0.6
035 1 0.6
R10 1 0.6
Total 165 100
Group 1 Breast: PR Allred Score Answer N Percent
X9 111 67.3 00 48 29.1
X8 3 1.8
01 2 1.2
07 1 0.6
Total 165 100
Group 1 Breast: HER2 IHC Summary Answer N Percent
0 154 93.3 9 8 4.8
1 1 0.6
2 1 0.6
8 1 0.6
Total 165 100
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 7
Group 1 Breast: HER2 ISH Summary Answer N Percent
9 133 80.6 0 27 16.4
8 5 3
Total 165 100
Group 1 Breast: HER2 Overall Summary Answer N Percent
0 157 95.2 9 8 4.8
Total 165 100
Group 1 Breast: HER2 ISH SP Copy No. Answer N Percent
XX.9 154 93.3
XX.8 5 3
99.9 3 1.8
0.0 2 1.2
XX.7 1 0.6
Total 165 100
Group 1 Breast: HER2 ISP DP Copy No Answer N Percent
XX.9 153 92.7 XX.8 5 3
99.9 4 2.4
0.0 2 1.2
XX.7 1 0.6
Total 165 100
Group 1 Breast: HER2 ISH DP Ratio Answer N Percent
XX.9 154 93.3 XX.8 5 3
Answer N Percent
99.9 3 1.8
0.0 2 1.2
1.3 1 0.6
Total 165 100
Group 1 Breast: Ki-67 Answer N Percent
XXX.9 155 93.9 XXX.8 3 1.8
99.9 2 1.2
XXX.7 2 1.2
0.0 1 0.6
000.9 1 0.6
15.0 1 0.6
Total 165 100
Group 1 Breast: Lymph Nodes Positive Axillary Level I-III
Answer N Percent
00 130 78.8 X9 24 14.5
99 5 3
X6 3 1.8
98 2 1.2
X8 1 0.6
Total 165 100
Group 1 Breast: Multigene Signature Method Answer N Percent
9 155 93.9
8 8 4.8
1 1 0.6
5 1 0.6
Total 165 100
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 8
Group 1 Breast: Multigene Signature Result Answer N Percent
X9 154 93.3 99 4 2.4
X8 4 2.4
00 1 0.6
09 1 0.6
X7 1 0.6
Total 165 100
Group 1 Breast: Oncotype DX Recur Score-DCIS Answer N Percent
XX6 106 64.2 XX9 54 32.7
XX8 4 2.4
000 1 0.6
Total 165 100
Group 1 Breast: Oncotype DX Recur Score Answer N Percent
XX9 162 98.2 000 1 0.6
XX4 1 0.6
XX6 1 0.6
Total 165 100
Group 1 Breast: Oncotype Dx Risk Level-DCIS Answer N Percent
6 107 64.8 9 53 32.1
8 4 2.4
1 1 0.6
Total 165 100
Group 1 Breast: Oncotype Dx Risk Level Invasive
Answer N Percent
9 158 95.8 6 4 2.4
8 2 1.2
1 1 0.6
Total 165 100
Group 1 Breast: Response Neoadjuv Therapy Answer N Percent
9 131 79.4 0 28 17
3 2 1.2
8 2 1.2
1 1 0.6
4 1 0.6
Total 165 100
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 9
Group 1-Colon and Rectum
Group 1 Colon and Rectum: Primary Site Answer N Percent
C186 148 88.1 C187 13 7.7
C185 3 1.8
C189 2 1.2
C182 1 0.6
C184 1 0.6
Total 168 100
Group 1 Colon and Rectum: Histology Answer N Percent
8140 163 97 8210 4 2.4
8500 1 0.6
Total 168 100
Group 1 Colon and Rectum: Behavior Answer N Percent
3 166 98.8
2 2 1.2
Total 168 100
Group 1 Colon and Rectum: Tumor Size Clinical Answer N Percent
999 156 92.9 070 3 1.8
000 2 1.2
007 2 1.2
050 2 1.2
003 1 0.6
005 1 0.6
700 1 0.6
Total 168 100
Group 1 Colon and Rectum: Tumor Size Pathologic
Answer N Percent
070 161 95.8 007 2 1.2
700 2 1.2
999 2 1.2
080 1 0.6
Total 168 100
Group 1 Colon and Rectum: EOD Primary Tumor
Answer N Percent
500 152 90.5 100 4 2.4
300 4 2.4
400 4 2.4
600 2 1.2
000 1 0.6
800 1 0.6
Total 168 100
Group 1 Colon and Rectum: EOD Regional Nodes
Answer N Percent
000 166 98.8 200 1 0.6
300 1 0.6
Total 168 100
Group 1 Colon and Rectum: Regional Nodes Positive
Answer N Percent
00 167 99.4
99 1 0.6
Total 168 100
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 10
Group 1 Colon and Rectum: EOD Mets Answer N Percent
00 165 98.2 10 2 1.2
99 1 0.6
Total 168 100
Group 1 Colon and Rectum: SS2018 Answer N Percent
2 150 89.3
1 9 5.4
3 4 2.4
0 2 1.2
4 2 1.2
9 1 0.6
Total 168 100
Group 1 Colon and Rectum: Grade Clinical Answer N Percent
2 125 74.4 9 40 23.8
3 2 1.2
4 1 0.6
Total 168 100
Group 1 Colon and Rectum: Grade Pathological Answer N Percent
2 143 85.1 3 25 14.9
Total 168 100
Group 1 Colon and Rectum: Grade Post Therapy
Answer N Percent
BLANK 141 83.9 9 24 14.3
Answer N Percent
2 2 1.2
1 1 0.6
Total 168 100
Group 1 Colon and Rectum: CEA PreTX Interpretation
Answer N Percent
9 153 91.1 7 11 6.5
0 2 1.2
2 1 0.6
8 1 0.6
Total 168 100
Group 1 Colon and Rectum: CEA PreTX Lab Value
Answer N Percent
XXXX.9 153 91.1 XXXX.7 10 6
XXXX.8 2 1.2
0.0 1 0.6
1.0 1 0.6
9999.9 1 0.6
Total 168 100
Group 1 Colon and Rectum: Circumferential Resection Margin
Answer N Percent
10.0 79 47
XX.1 55 32.7
XX.9 20 11.9
0.0 5 3
1.0 4 2.4
XX.0 3 1.8
20.0 1 0.6
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 11
Answer N Percent
XX.6 1 0.6
Total 168 100
Group 1 Colon and Rectum: KRAS Answer N Percent
9 159 94.6 0 5 3
8 4 2.4
Total 168 100
Group 1 Colon and Rectum: Microsatellite Instability
Answer N Percent
9 80 47.6 2 56 33.3
0 26 15.5
1 3 1.8
8 3 1.8
Total 168 100
Group 1 Colon and Rectum: Perineural Invasion
Answer N Percent
0 160 95.2 1 4 2.4
9 3 1.8
8 1 0.6
Total 168 100
Group 1 Colon and Rectum: Tumor Deposits Answer N Percent
00 155 92.3 X9 11 6.5
33 1 0.6
X8 1 0.6
Answer N Percent
Total 168 100
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 12
Group 1-Lung
Group 1 Lung: Primary Site Answer N Percent
C341 151 90.4 C348 13 7.8
C349 3 1.8
Total 167 100
Group 1 Lung: Histology Answer N Percent
8140 81 48.5 8230 48 28.7
8255 31 18.6
8551 4 2.4
8046 1 0.6
8500 1 0.6
8550 1 0.6
Total 167 100
Group 1 Lung: Behavior Answer N Percent
3 167 100 Total 167 100
Group 1 Lung: Tumor Size Clinical Answer N Percent
020 160 95.8 999 4 2.4
000 1 0.6
002 1 0.6
028 1 0.6
Total 167 100
Group 1 Lung: Tumor Size Pathologic Answer N Percent
020 162 97 999 2 1.2
000 1 0.6
002 1 0.6
025 1 0.6
Total 167 100
Group 1 Lung: EOD Primary Tumor Answer N Percent
300 120 71.9 100 25 15
400 14 8.4
200 2 1.2
450 2 1.2
000 1 0.6
500 1 0.6
700 1 0.6
999 1 0.6
Total 167 100
Group 1 Lung: EOD Regional Nodes Answer N Percent
300 127 76 400 28 16.8
800 6 3.6
700 3 1.8
000 2 1.2
999 1 0.6
Total 167 100
Group 1 Lung: Regional Nodes Positive Answer N Percent
04 121 72.5 03 39 23.4
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 13
Answer N Percent
00 2 1.2
01 2 1.2
05 1 0.6
07 1 0.6
99 1 0.6
Total 167 100
Group 1 Lung: EOD Mets Answer N Percent
00 161 96.4 10 5 3
99 1 0.6
Total 167 100
Group 1 Lung: SS2018 Answer N Percent
3 128 76.6 1 22 13.2
4 7 4.2
2 4 2.4
0 3 1.8
7 2 1.2
9 1 0.6
Total 167 100
Group 1 Lung: Grade Clinical Answer N Percent
9 165 98.8 1 1 0.6
2 1 0.6
Total 167 100
Group 1 Lung: Grade Pathological Answer N Percent
9 163 97.6
1 3 1.8
2 1 0.6
Total 167 100
Group 1 Lung: Grade Post Therapy Answer N Percent
BLANK 140 83.8 9 26 15.6
1 1 0.6
Total 167 100
Group 1 Lung: Separate Tumor Nodules Answer N Percent
0 142 85 9 9 5.4
7 7 4.2
3 3 1.8
1 2 1.2
2 2 1.2
4 2 1.2
Total 167 100
Group 1 Lung: Visceral and Parietal Pleural Invasion
Answer N Percent
0 160 95.8
1 3 1.8
9 3 1.8
4 1 0.6
Total 167 100
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 14
Group 1-Lymphoma (CLL/SLL)
Group 1 Lymphoma (CLL/SLL): Primary Site Answer N Percent
C421 101 62
C774 47 28.8
C420 8 4.9
C779 5 3.1
C770 1 0.6
C778 1 0.6
Total 163 100
Group 1 Lymphoma (CLL/SLL): Histology Answer N Percent
9823 163 100
Total 163 100
Group 1 Lymphoma (CLL/SLL): Behavior Answer N Percent
3 162 99.4 2 1 0.6
Total 163 100
Group 1 Lymphoma (CLL/SLL): Tumor Size Clinical
Answer N Percent
999 157 96.3 020 3 1.8
988 3 1.8
Total 163 100
Group 1 Lymphoma (CLL/SLL): Tumor Size Pathologic
Answer N Percent
999 161 98.8
988 2 1.2
Answer N Percent
Total 163 100
Group 1 Lymphoma (CLL/SLL): EOD Primary Tumor
Answer N Percent
100 74 45.4 800 56 34.4
300 14 8.6
700 10 6.1
999 7 4.3
600 2 1.2
Total 163 100
Group 1 Lymphoma (CLL/SLL): EOD Regional Nodes
Answer N Percent
888 163 100 Total 163 100
Group 1 Lymphoma (CLL/SLL): Regional Nodes Positive
Answer N Percent
99 159 97.5 88 2 1.2
98 2 1.2
Total 163 100
Group 1 Lymphoma (CLL/SLL): EOD Mets Answer N Percent
88 163 100 Total 163 100
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 15
Group 1 Lymphoma (CLL/SLL): SS2018 Answer N Percent
7 73 44.8 1 70 42.9
2 11 6.7
9 9 5.5
Total 163 100
Group 1 Lymphoma (CLL/SLL): Grade Clinical Answer N Percent
8 163 100 Total 163 100
Group 1 Lymphoma (CLL/SLL): Grade Pathological
Answer N Percent
8 163 100 Total 163 100
Group 1 Lymphoma (CLL/SLL): Grade Post Therapy
Answer N Percent
BLANK 104 63.8 8 59 36.2
Total 163 100
Group 1 Lymphoma (CLL/SLL): Adenopathy Answer N Percent
1 143 87.7 0 14 8.6
9 6 3.7
Total 163 100
Group 1 Lymphoma (CLL/SLL): Anemia Answer N Percent
0 126 77.3 9 21 12.9
1 15 9.2
6 1 0.6
Total 163 100
Group 1 Lymphoma (CLL/SLL): B symptoms Answer N Percent
1 117 71.8 6 26 16
0 14 8.6
9 6 3.7
Total 163 100
Group 1 Lymphoma (CLL/SLL): HIV Status Answer N Percent
9 135 82.8 0 26 16
1 1 0.6
8 1 0.6
Total 163 100
Group 1 Lymphoma (CLL/SLL): Lymphocytosis Answer N Percent
1 117 71.8 6 26 16
0 14 8.6
9 6 3.7
Total 163 100
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 16
Group 1 Lymphoma (CLL/SLL): NCCN International Prognostic Index (IPI)
Answer N Percent
X9 117 71.8 X2 29 17.8
X1 9 5.5
X8 3 1.8
02 2 1.2
00 1 0.6
01 1 0.6
X3 1 0.6
Total 163 100
Group 1 Lymphoma (CLL/SLL): Organomegaly Answer N Percent
0 143 87.7 9 18 11
1 2 1.2
Total 163 100
Group 1 Lymphoma (CLL/SLL): Thrombocytopenia
Answer N Percent
0 121 74.2 9 34 20.9
1 7 4.3
6 1 0.6
Total 163 100
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 17
Group 1-Melanoma Skin
Group 1 Melanoma Skin: Primary Site Answer N Percent
C445 159 98.1 C449 2 1.2
C447 1 0.6
Total 162 100
Group 1 Melanoma Skin: Histology Answer N Percent
8721 151 93.2 8720 11 6.8
Total 162 100
Group 1 Melanoma Skin: Behavior Answer N Percent
3 162 100 Total 162 100
Group 1 Melanoma Skin: Tumor Size Clinical Answer N Percent
999 124 76.5 002 19 11.7
021 15 9.3
009 1 0.6
010 1 0.6
014 1 0.6
020 1 0.6
Total 162 100
Group 1 Melanoma Skin: Tumor Size Pathologic
Answer N Percent
999 124 76.5 002 13 8
Answer N Percent
021 9 5.6
000 6 3.7
014 4 2.5
051 2 1.2
005 1 0.6
008 1 0.6
012 1 0.6
020 1 0.6
Total 162 100
Group 1 Melanoma Skin: EOD Primary Tumor Answer N Percent
300 147 90.7 100 6 3.7
500 4 2.5
200 2 1.2
400 2 1.2
999 1 0.6
Total 162 100
Group 1 Melanoma Skin: EOD Regional Nodes Answer N Percent
400 117 72.2 000 16 9.9
800 10 6.2
100 5 3.1
450 3 1.9
550 3 1.9
999 3 1.9
200 2 1.2
700 2 1.2
300 1 0.6
Total 162 100
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 18
Group 1 Melanoma Skin: Regional Nodes Positive
Answer N Percent
02 142 87.7 98 7 4.3
00 5 3.1
99 4 2.5
95 3 1.9
03 1 0.6
Total 162 100
Group 1 Melanoma Skin: EOD Mets Answer N Percent
00 144 88.9 10 16 9.9
50 1 0.6
90 1 0.6
Total 162 100
Group 1 Melanoma Skin: SS2018 Answer N Percent
3 114 70.4 1 18 11.1
4 15 9.3
7 10 6.2
0 2 1.2
2 2 1.2
9 1 0.6
Total 162 100
Group 1 Melanoma Skin: Grade Clinical Answer N Percent
9 162 100 Total 162 100
Group 1 Melanoma Skin: Grade Pathological Answer N Percent
9 162 100 Total 162 100
Group 1 Melanoma Skin: Grade Post Therapy Answer N Percent
BLANK 134 82.7 9 28 17.3
Total 162 100
Group 1 Melanoma Skin: Sentinel Lymph Nodes Examined
Answer N Percent
02 155 95.7 00 4 2.5
01 2 1.2
99 1 0.6
Total 162 100
Group 1 Melanoma Skin: Sentinel Lymph Nodes Positive
Answer N Percent
02 155 95.7 00 2 1.2
98 2 1.2
01 1 0.6
03 1 0.6
99 1 0.6
Total 162 100
Group 1 Melanoma Skin: Breslow Thickness Answer N Percent
2.1 131 80.9 02.1 17 10.5
2.5 4 2.5
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 19
Answer N Percent
21.0 3 1.9
2.0 1 0.6
5.1 1 0.6
7.8 1 0.6
99.9 1 0.6
A0.6 1 0.6
XX.1 1 0.6
XX.9 1 0.6
Total 162 100
Group 1 Melanoma Skin: Ulceration Answer N Percent
0 158 97.5 1 2 1.2
9 2 1.2
Total 162 100
Group 1 Melanoma Skin: LDH (Lactate Dehydrogenase) Pretreatment Lab Value
Answer N Percent
XXXXX.9 156 96.3 XXXXX.8 3 1.9
99999.9 2 1.2
99.9 1 0.6
Total 162 100
Group 1 Melanoma Skin: LDH (Lactate Dehydrogenase) Pretreatment Level
Answer N Percent
9 160 98.8 0 1 0.6
7 1 0.6
Total 162 100
Group 1 Melanoma Skin: LDH Upper Limits of Normal
Answer N Percent
XX9 147 90.7 999 11 6.8
XX8 3 1.9
014 1 0.6
Total 162 100
Group 1 Melanoma Skin: Mitotic Rate Melanoma
Answer N Percent
05 152 93.8 X9 4 2.5
02 2 1.2
01 1 0.6
25 1 0.6
99 1 0.6
X1 1 0.6
Total 162 100
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 20
Group 1-Ovary
Group 1 Ovary: Primary Site Answer N Percent
C569 159 100 Total 159 100
Group 1 Ovary: Histology Answer N Percent
8441 121 76.1 8461 33 20.8
8010 1 0.6
8140 1 0.6
8323 1 0.6
8460 1 0.6
8474 1 0.6
Total 159 100
Group 1 Ovary: Behavior Answer N Percent
3 158 99.4 2 1 0.6
Total 159 100
Group 1 Ovary: Tumor Size Clinical Answer N Percent
085 55 34.6 999 41 25.8
063 36 22.6
057 24 15.1
068 1 0.6
090 1 0.6
850 1 0.6
Total 159 100
Group 1 Ovary: Tumor Size Pathologic Answer N Percent
999 135 84.9 068 12 7.5
085 5 3.1
105 3 1.9
063 2 1.3
030 1 0.6
057 1 0.6
Total 159 100
Group 1 Ovary: EOD Primary Tumor Answer N Percent
700 134 84.3 750 8 5
450 5 3.1
300 3 1.9
650 3 1.9
100 2 1.3
400 2 1.3
200 1 0.6
350 1 0.6
Total 159 100
Group 1 Ovary: EOD Regional Nodes Answer N Percent
000 109 68.6 999 47 29.6
300 2 1.3
800 1 0.6
Total 159 100
Group 1 Ovary: Regional Nodes Positive Answer N Percent
98 125 78.6 00 21 13.2
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 21
Answer N Percent
99 13 8.2
Total 159 100
Group 1 Ovary: EOD Mets Answer N Percent
00 132 83 50 23 14.5
70 3 1.9
30 1 0.6
Total 159 100
Group 1 Ovary: SS2018 Answer N Percent
7 140 88.1 2 14 8.8
1 3 1.9
0 2 1.3
Total 159 100
Group 1 Ovary: Grade Clinical Answer N Percent
9 137 86.2 H 18 11.3
3 3 1.9
1 1 0.6
Total 159 100
Group 1 Ovary: Grade Pathological Answer N Percent
H 148 93.1 3 7 4.4
9 3 1.9
L 1 0.6
Total 159 100
Group 1 Ovary: Grade Post Therapy Answer N Percent
BLANK 135 84.9 9 18 11.3
H 5 3.1
3 1 0.6
Total 159 100
Group 1 Ovary: CA-125 PreTX Lab Value Answer N Percent
1 155 97.5 2 2 1.3
0 1 0.6
9 1 0.6
Total 159 100
Group 1 Ovary: FIGO Stage Answer N Percent
37 144 90.6 99 8 5
01 1 0.6
24 1 0.6
30 1 0.6
33 1 0.6
36 1 0.6
40 1 0.6
42 1 0.6
Total 159 100
Group 1 Ovary: Residual Tumor Volume Post Cytoreduction
Answer N Percent
00 86 54.1
99 22 13.8
97 19 11.9
92 12 7.5
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 22
Answer N Percent
93 6 3.8
30 5 3.1
10 4 2.5
90 3 1.9
40 1 0.6
98 1 0.6
Total 159 100
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 23
Group 1-Prostate
Group 1 Prostate: Primary Site Answer N Percent
C619 164 100 Total 164 100
Group 1 Prostate: Histology Answer N Percent
8140 153 93.3 8550 11 6.7
Total 164 100
Group 1 Prostate: Behavior Answer N Percent
3 163 99.4 2 1 0.6
Total 164 100
Group 1 Prostate: Tumor Size Clinical Answer N Percent
999 159 97 061 2 1.2
000 1 0.6
006 1 0.6
710 1 0.6
Total 164 100
Group 1 Prostate: Tumor Size Pathologic Answer N Percent
020 93 56.7 999 68 41.5
004 1 0.6
021 1 0.6
050 1 0.6
Total 164 100
Group 1 Prostate: EOD Primary Tumor Answer N Percent
220 25 15.2 120 24 14.6
400 20 12.2
600 20 12.2
350 19 11.6
210 15 9.1
250 13 7.9
300 9 5.5
200 6 3.7
150 5 3
100 3 1.8
500 2 1.2
000 1 0.6
110 1 0.6
999 1 0.6
Total 164 100
Group 1 Prostate: Prostate Path Exten Answer N Percent
600 75 45.7 400 70 42.7
350 6 3.7
300 4 2.4
000 3 1.8
500 2 1.2
999 2 1.2
900 1 0.6
950 1 0.6
Total 164 100
Group 1 Prostate: EOD Regional Nodes Answer N Percent
300 150 91.5
800 11 6.7
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 24
Answer N Percent
000 3 1.8
Total 164 100
Group 1 Prostate: Regional Nodes Positive Answer N Percent
01 152 92.7 00 5 3
02 5 3
98 1 0.6
99 1 0.6
Total 164 100
Group 1 Prostate: EOD Mets Answer N Percent
00 159 97 10 2 1.2
99 2 1.2
50 1 0.6
Total 164 100
Group 1 Prostate: SS2018 Answer N Percent
4 129 78.7 2 15 9.1
3 9 5.5
1 8 4.9
0 1 0.6
7 1 0.6
9 1 0.6
Total 164 100
Group 1 Prostate: Grade Clinical Answer N Percent
4 148 90.2 3 7 4.3
Answer N Percent
9 6 3.7
2 2 1.2
5 1 0.6
Total 164 100
Group 1 Prostate: Grade Pathological Answer N Percent
4 118 72 3 29 17.7
5 10 6.1
9 5 3
1 1 0.6
2 1 0.6
Total 164 100
Group 1 Prostate: Grade Post Therapy Answer N Percent
BLANK 137 83.5 9 23 14
2 2 1.2
3 1 0.6
4 1 0.6
Total 164 100
Group 1 Prostate: PSA Lab Value Answer N Percent
26.1 121 73.8 18.6 19 11.6
026.1 11 6.7
18.5 2 1.2
26.0 2 1.2
XXX.9 2 1.2
0.1 1 0.6
018.5 1 0.6
185.7 1 0.6
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 25
Answer N Percent
19.6 1 0.6
21.6 1 0.6
999.9 1 0.6
XXX.7 1 0.6
Total 164 100
Group 1 Prostate: Gleason Patterns Clinical Answer N Percent
44 157 95.7 12 2 1.2
43 2 1.2
X9 2 1.2
41 1 0.6
Total 164 100
Group 1 Prostate: Gleason Score Clinical Answer N Percent
08 156 95.1 04 2 1.2
07 2 1.2
X9 2 1.2
02 1 0.6
03 1 0.6
Total 164 100
Group 1 Prostate: Gleason Patterns Pathologic Answer N Percent
44 83 50.6 43 70 42.7
34 3 1.8
X7 2 1.2
12 1 0.6
19 1 0.6
41 1 0.6
45 1 0.6
Answer N Percent
X6 1 0.6
X9 1 0.6
Total 164 100
Group 1 Prostate: Gleason Score Pathologic Answer N Percent
08 85 51.8 07 70 42.7
03 3 1.8
09 2 1.2
X9 2 1.2
04 1 0.6
X7 1 0.6
Total 164 100
Group 1 Prostate: Gleason Tertiary Pattern Answer N Percent
50 143 87.2 X9 18 11
X7 2 1.2
20 1 0.6
Total 164 100
Group 1 Prostate: Number of Cores Examined Answer N Percent
13 114 69.5 12 31 18.9
06 7 4.3
03 3 1.8
X6 3 1.8
01 2 1.2
07 2 1.2
99 1 0.6
X9 1 0.6
Total 164 100
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 26
Group 1 Prostate: Number of Cores Positive Answer N Percent
06 145 88.4 13 7 4.3
01 3 1.8
X6 2 1.2
00 1 0.6
05 1 0.6
07 1 0.6
08 1 0.6
12 1 0.6
99 1 0.6
X9 1 0.6
Total 164 100
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 27
Group 1-Soft Tissue Abdomen and Thoracic
Group 1 Soft Tissue: Primary Site Answer N Percent
C220 143 91.1 C221 8 5.1
C494 3 1.9
C249 1 0.6
C493 1 0.6
C649 1 0.6
Total 157 100
Group 1 Soft Tissue: Histology Answer N Percent
8970 151 96.2 8140 1 0.6
8170 1 0.6
8560 1 0.6
8770 1 0.6
8790 1 0.6
8973 1 0.6
Total 157 100
Group 1 Soft Tissue: Behavior Answer N Percent
3 156 99.4 2 1 0.6
Total 157 100
Group 1 Soft Tissue: Tumor Size Clinical Answer N Percent
033 118 75.2 029 26 16.6
999 9 5.7
030 3 1.9
003 1 0.6
Answer N Percent
Total 157 100
Group 1 Soft Tissue: Tumor Size Pathologic Answer N Percent
031 120 76.4 030 22 14
999 8 5.1
033 4 2.5
006 1 0.6
029 1 0.6
061 1 0.6
Total 157 100
Group 1 Soft Tissue: EOD Primary Tumor Answer N Percent
100 147 93.6 200 5 3.2
300 2 1.3
500 1 0.6
700 1 0.6
999 1 0.6
Total 157 100
Group 1 Soft Tissue: EOD Regional Nodes Answer N Percent
000 133 84.7 999 24 15.3
Total 157 100
Group 1 Soft Tissue: Regional Nodes Positive Answer N Percent
98 128 81.5 00 25 15.9
99 4 2.5
Total 157 100
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 28
Group 1 Soft Tissue: EOD Mets Answer N Percent
00 155 98.7 70 1 0.6
99 1 0.6
Total 157 100
Group 1 Soft Tissue: SS2018 Answer N Percent
1 152 96.8 2 2 1.3
9 2 1.3
7 1 0.6
Total 157 100
Group 1 Soft Tissue: Grade Clinical Answer N Percent
9 157 100 Total 157 100
Group 1 Soft Tissue: Grade Pathological Answer N Percent
9 156 99.4 1 1 0.6
Total 157 100
Group 1 Soft Tissue: Grade Post Therapy Answer N Percent
BLANK 138 87.9 9 19 12.1
Total 157 100
Group 1 Soft Tissue: Bone Invasion Answer N Percent
0 136 86.6 9 18 11.5
8 2 1.3
1 1 0.6
Total 157 100
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 29
Group 1-Tongue Anterior
Group 1 Tongue Anterior: Primary Site Answer N Percent
C029 62 39.5 C023 53 33.8
C021 30 19.1
C020 6 3.8
C022 5 3.2
C028 1 0.6
Total 157 100
Group 1 Tongue Anterior: Histology Answer N Percent
8070 92 58.6 8072 57 36.3
8071 3 1.9
8073 2 1.3
8052 1 0.6
8086 1 0.6
8140 1 0.6
Total 157 100
Group 1 Tongue Anterior: Behavior Answer N Percent
3 157 100 Total 157 100
Group 1 Tongue Anterior: Tumor Size Clinical Answer N Percent
999 51 32.5 014 49 31.2
007 20 12.7
010 19 12.1
009 4 2.5
050 4 2.5
006 2 1.3
Answer N Percent
016 2 1.3
001 1 0.6
005 1 0.6
008 1 0.6
025 1 0.6
026 1 0.6
070 1 0.6
Total 157 100
Group 1 Tongue Anterior: Tumor Size Pathologic
Answer N Percent
009 147 93.6 090 4 2.5
001 2 1.3
999 2 1.3
004 1 0.6
007 1 0.6
Total 157 100
Group 1 Tongue Anterior: EOD Primary Tumor Answer N Percent
100 148 94.3 300 4 2.5
150 2 1.3
400 2 1.3
999 1 0.6
Total 157 100
Group 1 Tongue Anterior: EOD Regional Nodes Answer N Percent
100 118 75.2 150 19 12.1
800 7 4.5
000 4 2.5
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 30
Answer N Percent
200 4 2.5
300 2 1.3
400 2 1.3
999 1 0.6
Total 157 100
Group 1 Tongue Anterior: Regional Nodes Positive
Answer N Percent
01 152 96.8 00 2 1.3
95 1 0.6
98 1 0.6
99 1 0.6
Total 157 100
Group 1 Tongue Anterior: EOD Mets Answer N Percent
00 155 98.7 10 1 0.6
99 1 0.6
Total 157 100
Group 1 Tongue Anterior: SS2018 Answer N Percent
3 121 77.1 1 21 13.4
2 8 5.1
4 5 3.2
0 1 0.6
9 1 0.6
Total 157 100
Group 1 Tongue Anterior: Grade Clinical Answer N Percent
3 126 80.3 9 30 19.1
2 1 0.6
Total 157 100
Group 1 Tongue Anterior: Grade Pathological Answer N Percent
3 144 91.7 9 12 7.6
2 1 0.6
Total 157 100
Group 1 Tongue Anterior: Grade Post Therapy Answer N Percent
BLANK 137 87.3 9 16 10.2
3 2 1.3
1 1 0.6
2 1 0.6
Total 157 100
Group 1 Tongue Anterior: Extranodal Exten H&N Clin
Answer N Percent
0 93 59.2 7 44 28
9 15 9.6
1 3 1.9
2 2 1.3
Total 157 100
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 31
Group 1 Tongue Anterior: Extranodal Exten H&N Path
Answer N Percent
0.0 141 89.8 X.9 6 3.8
X.7 3 1.9
0.4 1 0.6
0.5 1 0.6
5.0 1 0.6
9.9 1 0.6
X.2 1 0.6
X.3 1 0.6
X.4 1 0.6
Total 157 100
Group 1 Tongue Anterior: LN Size Answer N Percent
0.5 97 61.8 XX.9 15 9.6
00.5 9 5.7
7.0 7 4.5
XX.3 5 3.2
8.0 4 2.5
0.7 3 1.9
0.8 3 1.9
07.0 3 1.9
0.0 2 1.3
05.0 2 1.3
5.0 2 1.3
99.9 1 0.6
XX.2 1 0.6
XX.5 1 0.6
XX.7 1 0.6
XX.8 1 0.6
Total 157 100
Group 1 Tongue Anterior: SEER SSF: Human Papilloma Virus (HPV) Status
Answer N Percent
9 77 49 0 47 29.9
8 26 16.6
1 4 2.5
2 1 0.6
3 1 0.6
4 1 0.6
Total 157 100
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 32
Group 2-Brain
Group 2 Brain: Primary Site Answer N Percent
C718 95 53.1 C712 37 20.7
C719 24 13.4
C714 21 11.7
C700 1 0.6
C713 1 0.6
Total 179 100
Group 2 Brain: Histology Answer N Percent
9440 176 98.3 9085 1 0.6
9441 1 0.6
9451 1 0.6
Total 179 100
Group 2 Brain: Behavior Answer N Percent
3 175 97.8 0 2 1.1
1 2 1.1
Total 179 100
Group 2 Brain: Tumor Size Clinical Answer N Percent
084 101 56.4 094 64 35.8
080 3 1.7
077 2 1.1
940 2 1.1
999 2 1.1
000 1 0.6
008 1 0.6
Answer N Percent
020 1 0.6
071 1 0.6
086 1 0.6
Total 179 100
Group 2 Brain: Tumor Size Pathologic Answer N Percent
999 106 59.2 070 43 24
020 18 10.1
084 3 1.7
094 2 1.1
000 1 0.6
008 1 0.6
022 1 0.6
055 1 0.6
077 1 0.6
080 1 0.6
200 1 0.6
Total 179 100
Group 2 Brain: EOD Primary Tumor Answer N Percent
100 141 78.8 500 26 14.5
999 9 5
700 2 1.1
800 1 0.6
Total 179 100
Group 2 Brain: EOD Regional Nodes Answer N Percent
888 179 100 Total 179 100
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 33
Group 2 Brain: Regional Nodes Positive Answer N Percent
99 155 86.6 98 12 6.7
00 11 6.1
88 1 0.6
Total 179 100
Group 2 Brain: EOD Mets Answer N Percent
00 174 97.2 70 2 1.1
99 2 1.1
10 1 0.6
Total 179 100
Group 2 Brain: SS2018 Answer N Percent
1 142 79.3 2 27 15.1
9 8 4.5
7 1 0.6
8 1 0.6
Total 179 100
Group 2 Brain: Grade Clinical Answer N Percent
4 139 77.7 9 29 16.2
H 10 5.6
D 1 0.6
Total 179 100
Group 2 Brain: Grade Pathological Answer N Percent
4 150 83.8 9 23 12.8
H 5 2.8
3 1 0.6
Total 179 100
Group 2 Brain: Grade Post Therapy Answer N Percent
BLANK 131 73.2 9 41 22.9
4 6 3.4
1 1 0.6
Total 179 100
Group 2 Brain: Brain Molecular Markers Answer N Percent
87 111 62 99 35 19.6
05 21 11.7
88 5 2.8
07 3 1.7
01 2 1.1
09 1 0.6
85 1 0.6
Total 179 100
Group 2 Brain: Chromosome 1p Status Answer N Percent
9 146 81.6 7 27 15.1
8 5 2.8
0 1 0.6
Total 179 100
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 34
Group 2 Brain: Chromosome 19q Status Answer N Percent
9 148 82.7 7 25 14
8 5 2.8
0 1 0.6
Total 179 100
Group 2 Brain: MGMT Answer N Percent
7 142 79.3 9 29 16.2
0 4 2.2
8 4 2.2
Total 179 100
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 35
Group 2-Breast
Group 2 Breast: Primary Site Answer N Percent
C508 100 56.2 C501 39 21.9
C505 23 12.9
C500 9 5.1
C509 4 2.2
C504 3 1.7
Total 178 100
Group 2 Breast: Histology Answer N Percent
8500 174 97.8 8000 1 0.6
8140 1 0.6
8521 1 0.6
8550 1 0.6
Total 178 100
Group 2 Breast: Behavior Answer N Percent
3 177 99.4 2 1 0.6
Total 178 100
Group 2 Breast: Tumor Size Clinical Answer N Percent
020 165 92.7 010 5 2.8
002 3 1.7
000 1 0.6
012 1 0.6
015 1 0.6
021 1 0.6
999 1 0.6
Answer N Percent
Total 178 100
Group 2 Breast: Tumor Size Pathologic Answer N Percent
004 134 75.3 999 19 10.7
001 8 4.5
020 5 2.8
010 4 2.2
040 3 1.7
000 2 1.1
990 2 1.1
002 1 0.6
Total 178 100
Group 2 Breast: EOD Primary Tumor Answer N Percent
100 167 93.8 000 7 3.9
999 2 1.1
300 1 0.6
400 1 0.6
Total 178 100
Group 2 Breast: EOD Regional Nodes Answer N Percent
000 130 73 070 42 23.6
999 3 1.7
150 2 1.1
100 1 0.6
Total 178 100
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 36
Group 2 Breast: Regional Nodes Positive Answer N Percent
00 172 96.6 01 3 1.7
98 2 1.1
99 1 0.6
Total 178 100
Group 2 Breast: EOD Mets Answer N Percent
00 176 98.9 05 2 1.1
Total 178 100
Group 2 Breast: SS2018 Answer N Percent
1 172 96.6 0 4 2.2
3 1 0.6
7 1 0.6
Total 178 100
Group 2 Breast: Grade Clinical Answer N Percent
3 160 89.9 1 9 5.1
9 4 2.2
2 2 1.1
H 2 1.1
C 1 0.6
Total 178 100
Group 2 Breast: Grade Pathological Answer N Percent
9 141 79.2 3 30 16.9
Answer N Percent
1 5 2.8
2 1 0.6
H 1 0.6
Total 178 100
Group 2 Breast: Sentinel Lymph Nodes Examined
Answer N Percent
01 167 93.8 00 5 2.8
98 3 1.7
02 1 0.6
03 1 0.6
99 1 0.6
Total 178 100
Group 2 Breast: Sentinel Lymph Nodes Positive Answer N Percent
00 173 97.2
01 4 2.2
99 1 0.6
Total 178 100
Group 2 Breast: ER Summary Answer N Percent
0 172 96.6 1 3 1.7
9 3 1.7
Total 178 100
Group 2 Breast: ER Percent Positive Answer N Percent
000 172 96.6 XX9 5 2.8
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 37
Answer N Percent
XX8 1 0.6
Total 178 100
Group 2 Breast: ER Allred Score Answer N Percent
00 172 96.6 X9 4 2.2
01 1 0.6
X8 1 0.6
Total 178 100
Group 2 Breast: PR Summary Answer N Percent
0 174 97.8 9 4 2.2
Total 178 100
Group 2 Breast: PR Percent Positive Answer N Percent
000 171 96.1 XX9 6 3.4
XX8 1 0.6
Total 178 100
Group 2 Breast: PR Allred Score Answer N Percent
00 170 95.5 X9 7 3.9
X8 1 0.6
Total 178 100
Group 2 Breast: HER2 IHC Summary Answer N Percent
1 110 61.8 0 41 23
2 23 12.9
9 3 1.7
8 1 0.6
Total 178 100
Group 2 Breast: HER2 ISH Summary Answer N Percent
0 163 91.6 9 13 7.3
2 1 0.6
8 1 0.6
Total 178 100
Group 2 Breast: HER2 Overall Summary Answer N Percent
0 166 93.3 1 7 3.9
9 4 2.2
7 1 0.6
Total 178 100
Group 2 Breast: HER2 ISH SP Copy No Answer N Percent
XX.9 131 73.6 3.7 14 7.9
2.8 9 5.1
0.0 7 3.9
XX.7 4 2.2
03.7 2 1.1
3.9 2 1.1
XX.1 2 1.1
00.1 1 0.6
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 38
Answer N Percent
1.0 1 0.6
1.3 1 0.6
2.6 1 0.6
4.0 1 0.6
4.2 1 0.6
XX.8 1 0.6
Total 178 100
Group 2 Breast: HER2 ISH DP Copy No Answer N Percent
3.7 70 39.3 XX.9 48 27
2.8 14 7.9
0.0 8 4.5
XX.7 8 4.5
3.9 6 3.4
03.7 5 2.8
1.3 5 2.8
4.0 5 2.8
1.0 2 1.1
00.1 1 0.6
04.0 1 0.6
3.1 1 0.6
4.1 1 0.6
4.2 1 0.6
XX.1 1 0.6
XX.8 1 0.6
Total 178 100
Group 2 Breast: HER2 ISH DP Copy No Answer N Percent
1.3 120 67.4 XX.9 25 14
01.3 14 7.9
0.0 5 2.8
Answer N Percent
XX.2 5 2.8
XX.7 3 1.7
2.0 2 1.1
0.1 1 0.6
00.1 1 0.6
3.7 1 0.6
XX.8 1 0.6
Total 178 100
Group 2 Breast: Ki-67 (MIB-1) Answer N Percent
XXX.9 168 94.4 0.0 3 1.7
XXX.8 3 1.7
XXX.7 2 1.1
8.0 1 0.6
99.9 1 0.6
Total 178 100
Group 2 Breast: Lymph Nodes Positive Axillary Level I-III
Answer N Percent
00 161 90.4 X9 11 6.2
01 2 1.1
99 2 1.1
98 1 0.6
X8 1 0.6
Total 178 100
Group 2 Breast: Multigene Signature Method Answer N Percent
9 144 80.9
5 25 14
1 4 2.2
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 39
Answer N Percent
6 3 1.7
3 1 0.6
8 1 0.6
Total 178 100
Group 2 Breast: Multigene Signature Results Answer N Percent
X9 138 77.5 X2 12 6.7
00 8 4.5
X7 8 4.5
99 7 3.9
X8 5 2.8
Total 178 100
Group 2 Breast: Oncotype DX Recur Score-DCIS Answer N Percent
XX6 115 64.6 XX9 55 30.9
000 5 2.8
XX8 2 1.1
010 1 0.6
Total 178 100
Group 2 Breast: Oncotype DX Recur Score Answer N Percent
XX9 168 94.4 000 5 2.8
009 2 1.1
XX6 2 1.1
XX7 1 0.6
Total 178 100
Group 2 Breast: Oncotype DX Risk Level-DCIS Answer N Percent
6 117 65.7 9 53 29.8
0 5 2.8
8 2 1.1
1 1 0.6
Total 178 100
Group 2 Breast: Oncotype DX Risk Level Invasive
Answer N Percent
9 167 93.8 0 8 4.5
8 2 1.1
6 1 0.6
Total 178 100
Group 2 Breast: Response Neoadjuv Therapy Answer N Percent
3 76 42.7 2 51 28.7
9 28 15.7
0 14 7.9
1 7 3.9
4 1 0.6
8 1 0.6
Total 178 100
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 40
Group 2-Colon and Rectum
Group 2 Colon and Rectum: Primary Site Answer N Percent
C182 70 39.3 C183 59 33.1
C184 43 24.2
C188 2 1.1
C189 2 1.1
C180 1 0.6
C187 1 0.6
Total 178 100
Group 2 Colon and Rectum: Histology Answer N Percent
8480 135 75.8 8140 40 22.5
8149 1 0.6
8253 1 0.6
8486 1 0.6
Total 178 100
Group 2 Colon and Rectum: Behavior Answer N Percent
3 176 98.9 2 2 1.1
Total 178 100
Group 2 Colon and Rectum: Tumor Size Clinical Answer N Percent
040 155 87.1 999 16 9
004 3 1.7
000 2 1.1
047 1 0.6
060 1 0.6
Total 178 100
Group 2 Colon and Rectum: Tumor Size Pathologic
Answer N Percent
047 171 96.1 000 2 1.1
001 1 0.6
005 1 0.6
050 1 0.6
089 1 0.6
470 1 0.6
Total 178 100
Group 2 Colon and Rectum: EOD Primary Tumor
Answer N Percent
400 97 54.5 300 64 36
200 7 3.9
000 4 2.2
100 3 1.7
050 2 1.1
999 1 0.6
Total 178 100
Group 2 Colon and Rectum: EOD Regional Nodes
Answer N Percent
000 175 98.3 300 2 1.1
999 1 0.6
Total 178 100
Group 2 Colon and Rectum: Regional Nodes Positive
Answer N Percent
00 176 98.9 07 1 0.6
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 41
Answer N Percent
99 1 0.6
Total 178 100
Group 2 Colon and Rectum: EOD Mets Answer N Percent
00 177 99.4 10 1 0.6
Total 178 100
Group 2 Colon and Rectum: SS2018 Answer N Percent
2 105 59 1 64 36
0 3 1.7
3 3 1.7
4 1 0.6
7 1 0.6
9 1 0.6
Total 178 100
Group 2 Colon and Rectum: Grade Clinical Answer N Percent
2 169 94.9 9 5 2.8
1 2 1.1
3 2 1.1
Total 178 100
Group 2 Colon and Rectum: Grade Pathological Answer N Percent
2 173 97.2 3 3 1.7
1 1 0.6
9 1 0.6
Answer N Percent
Total 178 100
Group 2 Colon and Rectum: Grade Post Therapy
Answer N Percent
BLANK 138 77.5 9 31 17.4
2 8 4.5
4 1 0.6
Total 178 100
Group 2 Colon and Rectum: CEA PreTX Lab Value
Answer N Percent
XXXX.9 169 94.9 XXXX.8 4 2.2
0.0 3 1.7
999.9 1 0.6
9999.9 1 0.6
Total 178 100
Group 2 Colon and Rectum: Circumferential Resection Margin
Answer N Percent
6.0 103 57.9 XX.1 21 11.8
0.6 14 7.9
XX.9 12 6.7
06.0 9 5.1
0.0 6 3.4
XX.6 4 2.2
00.6 3 1.7
2.0 3 1.7
XX.8 2 1.1
99.1 1 0.6
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 42
Answer N Percent
Total 178 100
Group 2 Colon and Rectum: KRAS Answer N Percent
9 174 97.8 0 2 1.1
8 2 1.1
Total 178 100
Group 2 Colon and Rectum: Microsatellite Instability
Answer N Percent
2 156 87.6 0 11 6.2
1 8 4.5
9 2 1.1
8 1 0.6
Total 178 100
Group 2 Colon and Rectum: Perineural Invasion
Answer N Percent
0 172 96.6
9 3 1.7
8 2 1.1
1 1 0.6
Total 178 100
Group 2 Colon: Tumor Deposits Answer N Percent
00 166 93.3 X9 9 5.1
X8 2 1.1
99 1 0.6
Total 178 100
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 43
Group 2-Lung
Group 2 Lung: Primary Site Answer N Percent
C343 88 51.5 C340 66 38.6
C348 7 4.1
C349 6 3.5
C341 4 2.3
Total 171 100
Group 2 Lung: Histology Answer N Percent
8072 134 78.4 8070 30 17.5
8071 2 1.2
8046 1 0.6
8073 1 0.6
8230 1 0.6
8480 1 0.6
8700 1 0.6
Total 171 100
Group 2 Lung: Behavior Answer N Percent
3 170 99.4 2 1 0.6
Total 171 100
Group 2 Lung: Tumor Size Clinical Answer N Percent
052 118 69 047 24 14
071 10 5.8
070 4 2.3
999 3 1.8
006 2 1.2
Answer N Percent
065 2 1.2
470 2 1.2
007 1 0.6
040 1 0.6
045 1 0.6
057 1 0.6
074 1 0.6
094 1 0.6
Total 171 100
Group 2 Lung: Tumor Size Pathological Answer N Percent
065 165 96.5 000 1 0.6
007 1 0.6
035 1 0.6
047 1 0.6
067 1 0.6
650 1 0.6
Total 171 100
Group 2 Lung: EOD Primary Tumor Answer N Percent
300 128 74.9 400 23 13.5
800 7 4.1
000 6 3.5
700 6 3.5
999 1 0.6
Total 171 100
Group 2 Lung: EOD Regional Nodes Answer N Percent
300 128 74.9
400 23 13.5
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 44
Answer N Percent
800 7 4.1
000 6 3.5
700 6 3.5
999 1 0.6
Total 171 100
Group 2 Lung: Regional Nodes Positive Answer N Percent
03 163 95.3 00 4 2.3
01 2 1.2
97 1 0.6
99 1 0.6
Total 171 100
Group 2 Lung: EOD Mets Answer N Percent
00 159 93 10 11 6.4
20 1 0.6
Total 171 100
Group 2 Lung: SS2018 Answer N Percent
3 84 49.1 4 55 32.2
7 12 7
2 10 5.8
1 9 5.3
0 1 0.6
Total 171 100
Group 2 Lung: Grade Clinical Answer N Percent
2 132 77.2 9 35 20.5
1 4 2.3
Total 171 100
Group 2 Lung: Grade Pathological Answer N Percent
2 165 96.5 9 4 2.3
3 2 1.2
Total 171 100
Group 2 Lung: Grade Post Therapy Answer N Percent
BLANK 136 79.5 9 31 18.1
2 3 1.8
1 1 0.6
Total 171 100
Group 2 Lung: Separate Tumor Nodules Answer N Percent
0 138 80.7 7 11 6.4
1 7 4.1
2 5 2.9
3 4 2.3
9 3 1.8
4 2 1.2
8 1 0.6
Total 171 100
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 45
Group 2 Lung: Visceral and Parietal Pleural Invasion
Answer N Percent
0 161 94.2 1 4 2.3
3 2 1.2
2 1 0.6
4 1 0.6
8 1 0.6
9 1 0.6
Total 171 100
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 46
Group 2-Lymphoma (CLL/SLL)
Group 2 Lymphoma (CLL/SLL): Primary Site Answer N Percent
C421 88 52.7 C778 54 32.3
C774 14 8.4
C779 6 3.6
C739 2 1.2
C770 2 1.2
C776 1 0.6
Total 167 100
Group 2 Lymphoma (CLL/SLL): Histology Answer N Percent
9823 167 100 Total 167 100
Group 2 Lymphoma (CLL/SLL): Behavior Answer N Percent
3 164 98.2 2 3 1.8
Total 167 100
Group 2 Lymphoma (CLL/SLL): Tumor Size Clinical
Answer N Percent
999 156 93.4 000 3 1.8
024 2 1.2
988 2 1.2
998 2 1.2
023 1 0.6
031 1 0.6
Total 167 100
Group 2 Lymphoma (CLL/SLL): Tumor Size Pathologic
Answer N Percent
999 160 95.8 000 2 1.2
988 2 1.2
998 2 1.2
024 1 0.6
Total 167 100
Group 2 Lymphoma (CLL/SLL): EOD Primary Tumor
Answer N Percent
600 74 44.3 800 45 26.9
100 15 9
700 13 7.8
999 11 6.6
300 6 3.6
400 2 1.2
200 1 0.6
Total 167 100
Group 2 Lymphoma (CLL/SLL): EOD Regional Nodes
Answer N Percent
888 167 100 Total 167 100
Group 2 Lymphoma (CLL/SLL): Regional Nodes Positive
Answer N Percent
99 159 95.2 02 3 1.8
00 2 1.2
01 1 0.6
88 1 0.6
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 47
Answer N Percent
98 1 0.6
Total 167 100
Group 2 Lymphoma (CLL/SLL): EOD Mets Answer N Percent
88 167 100 Total 167 100
Group 2 Lymphoma (CLL/SLL): SS2018 Answer N Percent
7 138 82.6 1 16 9.6
9 7 4.2
2 6 3.6
Total 167 100
Group 2 Lymphoma (CLL/SLL): Grade Clinical Answer N Percent
8 167 100 Total 167 100
Group 2 Lymphoma (CLL/SLL): Grade Pathological
Answer N Percent
8 167 100 Total 167 100
Group 2 Lymphoma (CLL/SLL): Grade Post Therapy
Answer N Percent
BLANK 95 56.9
8 72 43.1
Total 167 100
Group 2 Lymphoma (CLL/SLL): Adenopathy Answer N Percent
1 158 94.6 9 7 4.2
0 2 1.2
Total 167 100
Group 2 Lymphoma (CLL/SLL): Anemia Answer N Percent
9 125 74.9 0 34 20.4
1 7 4.2
7 1 0.6
Total 167 100
Group 2 Lymphoma (CLL/SLL): B Symptoms Answer N Percent
1 150 89.8 0 8 4.8
9 5 3
8 4 2.4
Total 167 100
Group 2 Lymphoma (CLL/SLL): HIV Status Answer N Percent
9 142 85 0 23 13.8
8 2 1.2
Total 167 100
Group 2 Lymphoma (CLL/SLL): Lymphocytosis Answer N Percent
6 62 37.1 1 54 32.3
9 40 24
0 9 5.4
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 48
Answer N Percent
7 2 1.2
Total 167 100
Group 2 Lymphoma (CLL/SLL): NCCN International Prognostic Index (IPI)
Answer N Percent
X9 127 76 X4 24 14.4
04 5 3
X8 5 3
00 2 1.2
01 2 1.2
X1 2 1.2
Total 167 100
Group 2 Lymphoma (CLL/SLL): Organomegaly Answer N Percent
0 130 77.8 9 34 20.4
1 3 1.8
Total 167 100
Group 2 Lymphoma (CLL/SLL): Thrombocytopenia
Answer N Percent
9 136 81.4 0 28 16.8
1 2 1.2
6 1 0.6
Total 167 100
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 49
Group 2-Melanoma Skin
Group 2 Melanoma Skin: Primary Site Answer N Percent
C445 167 97.1 C449 2 1.2
C446 1 0.6
C448 1 0.6
C632 1 0.6
Total 172 100
Group 2 Melanoma Skin: Histology Answer N Percent
8720 172 100 Total 172 100
Group 2 Melanoma Skin: Behavior Answer N Percent
3 172 100 Total 172 100
Group 2 Melanoma Skin: Tumor Size Clinical Answer N Percent
010 51 29.7 999 41 23.8
020 34 19.8
015 19 11
009 12 7
029 3 1.7
005 2 1.2
000 1 0.6
002 1 0.6
008 1 0.6
019 1 0.6
025 1 0.6
078 1 0.6
081 1 0.6
Answer N Percent
090 1 0.6
100 1 0.6
990 1 0.6
Total 172 100
Group 2 Melanoma Skin: Tumor Size Pathologic
Answer N Percent
999 83 48.3 010 42 24.4
020 16 9.3
029 10 5.8
015 6 3.5
000 4 2.3
003 3 1.7
078 3 1.7
002 1 0.6
008 1 0.6
009 1 0.6
080 1 0.6
100 1 0.6
Total 172 100
Group 2 Melanoma Skin: EOD Primary Tumor Answer N Percent
400 77 44.8 999 44 25.6
300 27 15.7
100 11 6.4
500 8 4.7
200 5 2.9
Total 172 100
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 50
Group 2 Melanoma Skin: EOD Regional Nodes Answer N Percent
400 108 62.8 450 25 14.5
000 14 8.1
100 7 4.1
200 5 2.9
999 5 2.9
800 4 2.3
300 3 1.7
350 1 0.6
Total 172 100
Group 2 Melanoma Skin: Regional Nodes Positive
Answer N Percent
02 131 76.2 00 14 8.1
01 10 5.8
98 9 5.2
03 2 1.2
97 2 1.2
99 2 1.2
04 1 0.6
95 1 0.6
Total 172 100
Group 2 Melanoma Skin: EOD Mets Answer N Percent
00 163 94.8 10 8 4.7
70 1 0.6
Total 172 100
Group 2 Melanoma Skin: SS2018 Answer N Percent
3 122 70.9 1 21 12.2
4 13 7.6
2 5 2.9
7 5 2.9
9 4 2.3
0 2 1.2
Total 172 100
Group 2 Melanoma Skin: Grade Clinical Answer N Percent
9 171 99.4
C 1 0.6
Total 172 100
Group 2 Melanoma Skin: Grade Pathological Answer N Percent
9 171 99.4 B 1 0.6
Total 172 100
Group 2 Melanoma Skin: Grade Post Therapy Answer N Percent
BLANK 135 78.5 9 37 21.5
Total 172 100
Group 2 Melanoma Skin: Sentinel Lymph Nodes Examined
Answer N Percent
03 98 57 01 42 24.4
02 15 8.7
00 5 2.9
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 51
Answer N Percent
98 5 2.9
04 4 2.3
99 2 1.2
95 1 0.6
Total 172 100
Group 2 Melanoma Skin: Sentinel Lymph Nodes Positive
Answer N Percent
02 104 60.5 01 47 27.3
00 14 8.1
98 2 1.2
99 2 1.2
03 1 0.6
04 1 0.6
95 1 0.6
Total 172 100
Group 2 Melanoma Skin: Breslow Thickness Answer N Percent
2.9 136 79.1 02.9 24 14
29.0 3 1.7
0.3 2 1.2
00.8 1 0.6
1.0 1 0.6
2.4 1 0.6
2.5 1 0.6
3.0 1 0.6
A2.9 1 0.6
XX.8 1 0.6
Total 172 100
Group 2 Melanoma Skin: Ulceration Answer N Percent
0 169 98.3 8 2 1.2
9 1 0.6
Total 172 100
Group 2 Melanoma Skin: LDH (Lactate Dehydrogenase) Pretreatment Lab Value
Answer N Percent
XXXXX.9 162 94.2 0.0 4 2.3
9.9 2 1.2
XXXXX.8 2 1.2
999.9 1 0.6
99999.9 1 0.6
Total 172 100
Group 2 Melanoma Skin: LDH (Lactate Dehydrogenase) Pretreatment Level
Answer N Percent
9 171 99.4 0 1 0.6
Total 172 100
Group 2 Melanoma Skin: LDH Upper Limits of Normal
Answer N Percent
XX9 160 93 999 8 4.7
XX8 4 2.3
Total 172 100
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 52
Group 2 Melanoma Skin: Mitotic Rate Melanoma
Answer N Percent
01 159 92.4 X9 4 2.3
X8 3 1.7
00 1 0.6
03 1 0.6
05 1 0.6
10 1 0.6
99 1 0.6
X3 1 0.6
Total 172 100
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 53
Group 2-Ovary
Group 2 Ovary: Primary Site Answer N Percent
C569 166 100 Total 166 100
Group 2 Ovary: Histology Answer N Percent
8380 143 86.1 8140 13 7.8
8263 2 1.2
8323 2 1.2
8570 2 1.2
8441 1 0.6
8460 1 0.6
8480 1 0.6
8720 1 0.6
Total 166 100
Group 2 Ovary: Behavior Answer N Percent
3 166 100 Total 166 100
Group 2 Ovary: Tumor Size Clinical Answer N Percent
110 132 79.5 011 11 6.6
999 7 4.2
060 6 3.6
100 5 3
000 2 1.2
989 2 1.2
111 1 0.6
Total 166 100
Group 2 Ovary: Tumor Size Pathologic Answer N Percent
105 143 86.1 011 7 4.2
999 4 2.4
110 3 1.8
000 2 1.2
006 1 0.6
060 1 0.6
085 1 0.6
100 1 0.6
101 1 0.6
600 1 0.6
989 1 0.6
Total 166 100
Group 2 Ovary: EOD Primary Tumor Answer N Percent
700 105 63.3 750 48 28.9
400 3 1.8
600 3 1.8
100 2 1.2
150 2 1.2
999 2 1.2
800 1 0.6
Total 166 100
Group 2 Ovary: EOD Regional Nodes Answer N Percent
400 56 33.7 999 54 32.5
000 25 15.1
800 15 9
500 11 6.6
300 5 3
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 54
Answer N Percent
Total 166 100
Group 2 Ovary: Regional Nodes Positive Answer N Percent
98 134 80.7 00 16 9.6
99 10 6
97 4 2.4
02 1 0.6
03 1 0.6
Total 166 100
Group 2 Ovary: EOD Mets Answer N Percent
50 97 58.4 00 43 25.9
70 22 13.3
30 3 1.8
99 1 0.6
Total 166 100
Group 2 Ovary: SS2018 Answer N Percent
7 148 89.2 4 7 4.2
0 3 1.8
2 3 1.8
9 3 1.8
3 2 1.2
Total 166 100
Group 2 Ovary: Grade Clinical Answer N Percent
9 148 89.2 3 11 6.6
Answer N Percent
2 5 3
1 1 0.6
H 1 0.6
Total 166 100
Group 2 Ovary: Grade Pathological Answer N Percent
3 150 90.4 9 9 5.4
2 5 3
1 1 0.6
H 1 0.6
Total 166 100
Group 2 Ovary: Grade Post Therapy Answer N Percent
BLANK 135 81.3 9 29 17.5
1 1 0.6
2 1 0.6
Total 166 100
Group 2 Ovary: CA-125 PreTX Lab Value Answer N Percent
9 161 97 8 2 1.2
0 1 0.6
1 1 0.6
2 1 0.6
Total 166 100
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 55
Group 2 Ovary: FIGO Stage Answer N Percent
37 125 75.3 42 16 9.6
99 15 9
02 3 1.8
30 2 1.2
40 2 1.2
98 2 1.2
01 1 0.6
Total 166 100
Group 2 Ovary: Residual Tumor Volume Post Cytoreduction
Answer N Percent
99 72 43.4 97 32 19.3
90 19 11.4
92 17 10.2
00 12 7.2
98 7 4.2
30 4 2.4
10 1 0.6
40 1 0.6
91 1 0.6
Total 166 100
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 56
Group 2-Prostate
Group 2 Prostate: Primary Site Answer N Percent
C619 172 100 Total 172 100
Group 2 Prostate: Histology Answer N Percent
8140 161 93.6 8550 7 4.1
8255 2 1.2
8500 1 0.6
8720 1 0.6
Total 172 100
Group 2 Prostate: Behavior Answer N Percent
C619 172 100 Total 172 100
Group 2 Prostate: Tumor Size Clinical Answer N Percent
999 169 98.3 000 2 1.2
046 1 0.6
Total 172 100
Group 2 Prostate: Tumor Size Pathologic Answer N Percent
999 122 70.9 020 37 21.5
046 8 4.7
000 2 1.2
001 1 0.6
040 1 0.6
Answer N Percent
136 1 0.6
Total 172 100
Group 2 Prostate: EOD Primary Tumor Answer N Percent
200 43 25 350 39 22.7
120 31 18
300 17 9.9
250 15 8.7
210 6 3.5
500 5 2.9
999 5 2.9
150 4 2.3
100 3 1.7
400 2 1.2
110 1 0.6
220 1 0.6
Total 172 100
Group 2 Prostate: Prostate Path Exten Answer N Percent
350 127 73.8 500 17 9.9
300 15 8.7
000 5 2.9
250 3 1.7
400 3 1.7
600 1 0.6
999 1 0.6
Total 172 100
Group 2 Prostate: EOD Regional Nodes Answer N Percent
000 170 98.8
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 57
Answer N Percent
300 1 0.6
999 1 0.6
Total 172 100
Group 2 Prostate: Regional Nodes Positive Answer N Percent
00 170 98.8 04 1 0.6
98 1 0.6
Total 172 100
Group 2 Prostate: EOD Mets Answer N Percent
00 170 98.8 10 2 1.2
Total 172 100
Group 2 Prostate: SS2018 Answer N Percent
2 129 75 1 38 22.1
3 2 1.2
0 1 0.6
7 1 0.6
9 1 0.6
Total 172 100
Group 2 Prostate: Grade Clinical Answer N Percent
2 166 96.5 9 3 1.7
3 2 1.2
B 1 0.6
Total 172 100
Group 2 Prostate: Grade Pathological Answer N Percent
2 166 96.5 3 3 1.7
9 3 1.7
Total 172 100
Group 2 Prostate: Grade Post Therapy Answer N Percent
BLANK 136 79.1 9 32 18.6
2 3 1.7
1 1 0.6
Total 172 100
Group 2 Prostate: PSA Lab Value Answer N Percent
13.6 157 91.3 013.6 9 5.2
136.0 2 1.2
000.9 1 0.6
13.7 1 0.6
13.8 1 0.6
14.0 1 0.6
Total 172 100
Group 2 Prostate: Gleason Patterns Clinical Answer N Percent
34 168 97.7 22 1 0.6
43 1 0.6
X8 1 0.6
X9 1 0.6
Total 172 100
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 58
Group 2 Prostate: Gleason Score Clinical Answer N Percent
07 166 96.5 02 3 1.7
X7 1 0.6
X8 1 0.6
X9 1 0.6
Total 172 100
Group 2 Prostate: Gleason Patterns Pathologic Answer N Percent
34 169 98.3 X8 2 1.2
43 1 0.6
Total 172 100
Group 2 Prostate: Gleason Score Pathologic Answer N Percent
07 168 97.7 02 2 1.2
03 1 0.6
X8 1 0.6
Total 172 100
Group 2 Prostate: Gleason Tertiary Pattern Answer N Percent
X9 148 86 X8 21 12.2
10 1 0.6
20 1 0.6
40 1 0.6
Total 172 100
Group 2 Prostate: Number of Cores Examined Answer N Percent
X6 54 31.4 02 27 15.7
06 24 14
20 22 12.8
12 13 7.6
04 9 5.2
08 8 4.7
X9 6 3.5
19 3 1.7
10 2 1.2
99 2 1.2
09 1 0.6
17 1 0.6
Total 172 100
Group 2 Prostate: Number of Cores Positive Answer N Percent
04 88 51.2 02 69 40.1
X6 5 2.9
00 3 1.7
X9 3 1.7
12 2 1.2
06 1 0.6
08 1 0.6
Total 172 100
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 59
Group 2-Soft Tissue Abdomen and Thoracic
Group 2 Soft Tissue: Primary Site Answer N Percent
C494 84 51.5 C495 75 46
C493 2 1.2
C151 1 0.6
C160 1 0.6
Total 163 100
Group 2 Soft Tissue: Histology Answer N Percent
8811 136 83.4 8840 7 4.3
8800 6 3.7
8810 4 2.5
8830 4 2.5
8895 2 1.2
8000 1 0.6
8140 1 0.6
8710 1 0.6
8813 1 0.6
Total 163 100
Group 2 Soft Tissue: Behavior Answer N Percent
3 161 98.8 1 1 0.6
2 1 0.6
Total 163 100
Group 2 Soft Tissue: Tumor Size Clinical Answer N Percent
100 75 46 098 34 20.9
Answer N Percent
097 19 11.7
150 15 9.2
010 14 8.6
000 1 0.6
015 1 0.6
101 1 0.6
125 1 0.6
130 1 0.6
800 1 0.6
Total 163 100
Group 2 Soft Tissue: Tumor Size Pathologic Answer N Percent
130 136 83.4 013 14 8.6
150 4 2.5
999 4 2.5
000 2 1.2
015 2 1.2
098 1 0.6
Total 163 100
Group 2 Soft Tissue: EOD Primary Tumor Answer N Percent
100 89 54.6 400 25 15.3
200 21 12.9
500 18 11
550 4 2.5
300 3 1.8
999 2 1.2
600 1 0.6
Total 163 100
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 60
Group 2 Soft Tissue: EOD Regional Nodes Answer N Percent
000 142 87.1 999 21 12.9
Total 163 100
Group 2 Soft Tissue: Regional Nodes Positive Answer N Percent
98 131 80.4 00 29 17.8
99 3 1.8
Total 163 100
Group 2 Soft Tissue: EOD Mets Answer N Percent
00 162 99.4
70 1 0.6
Total 163 100
Group 2 Soft Tissue: SS2018 Answer N Percent
1 96 58.9 2 65 39.9
7 1 0.6
9 1 0.6
Total 163 100
Group 2 Soft Tissue: Grade Clinical Answer N Percent
9 67 41.1 3 63 38.7
D 17 10.4
C 12 7.4
1 2 1.2
2 1 0.6
A 1 0.6
Answer N Percent
Total 163 100
Group 2 Soft Tissue: Grade Pathological Answer N Percent
3 141 86.5 9 7 4.3
1 6 3.7
C 4 2.5
D 4 2.5
A 1 0.6
Total 163 100
Group 2 Soft Tissue: Grade Post Therapy Answer N Percent
BLANK 139 85.3 9 21 12.9
3 2 1.2
2 1 0.6
Total 163 100
Group 2 Soft Tissue: Bone Invasion Answer N Percent
0 159 97.5 1 3 1.8
8 1 0.6
Total 163 100
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 61
Group 2-Soft Tongue Anterior
Group 2 Tongue Anterior: Primary Site Answer N Percent
C022 93 57.4 C023 33 20.4
C029 23 14.2
C021 6 3.7
C020 4 2.5
C028 3 1.9
Total 162 100
Group 2 Tongue Anterior: Histology Answer N Percent
8071 92 56.8 8070 65 40.1
8085 2 1.2
8052 1 0.6
8171 1 0.6
8982 1 0.6
Total 162 100
Group 2 Tongue Anterior: Behavior Answer N Percent
3 160 98.8 1 1 0.6
2 1 0.6
Total 162 100
Group 2 Tongue Anterior: Tumor Size Clinical Answer N Percent
050 100 61.7 025 43 26.5
999 6 3.7
014 5 3.1
250 2 1.2
003 1 0.6
Answer N Percent
012 1 0.6
015 1 0.6
020 1 0.6
065 1 0.6
990 1 0.6
Total 162 100
Group 2 Tongue Anterior: Tumor Size Pathologic
Answer N Percent
014 141 87 007 7 4.3
019 4 2.5
050 4 2.5
140 2 1.2
000 1 0.6
001 1 0.6
025 1 0.6
065 1 0.6
Total 162 100
Group 2 Tongue Anterior: EOD Primary Tumor Answer N Percent
100 145 89.5 150 6 3.7
200 5 3.1
300 3 1.9
000 2 1.2
999 1 0.6
Total 162 100
Group 2 Tongue Anterior: EOD Regional Nodes Answer N Percent
000 139 85.8 100 13 8
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 62
Answer N Percent
999 6 3.7
300 2 1.2
150 1 0.6
450 1 0.6
Total 162 100
Group 2 Tongue Anterior: Regional Nodes Positive
Answer N Percent
00 136 84 98 20 12.3
01 3 1.9
99 2 1.2
41 1 0.6
Total 162 100
Group 2 Tongue Anterior: EOD Mets Answer N Percent
00 162 100 Total 162 100
Group 2 Tongue Anterior: SS2018 Answer N Percent
1 146 90.1 3 9 5.6
0 2 1.2
2 2 1.2
9 2 1.2
7 1 0.6
Total 162 100
Group 2 Tongue Anterior: Grade Clinical Answer N Percent
9 99 61.1 1 59 36.4
2 2 1.2
3 2 1.2
Total 162 100
Group 2 Tongue Anterior: Grade Pathological Answer N Percent
3 81 50 1 73 45.1
9 5 3.1
2 3 1.9
Total 162 100
Group 2 Tongue Anterior: Grade Post Therapy Answer N Percent
BLANK 135 83.3 9 18 11.1
3 7 4.3
1 2 1.2
Total 162 100
Group 2 Tongue Anterior: Extranodal Exten H&N Clin
Answer N Percent
0 74 45.7 7 38 23.5
9 27 16.7
1 19 11.7
8 3 1.9
2 1 0.6
Total 162 100
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 63
Group 2 Tongue Anterior: Extranodal Exten H&N Path
Answer N Percent
X.7 117 72.2 X.9 28 17.3
0.0 11 6.8
9.9 2 1.2
X.8 2 1.2
0.8 1 0.6
X.1 1 0.6
Total 162 100
Group 2 Tongue Anterior: LN Size Answer N Percent
0.0 132 81.5 XX.9 12 7.4
1.2 4 2.5
12.0 4 2.5
XX.8 2 1.2
00.8 1 0.6
00.9 1 0.6
01.2 1 0.6
1.5 1 0.6
22.0 1 0.6
6.3 1 0.6
9.9 1 0.6
XX.1 1 0.6
Total 162 100
Group 2 Tongue Anterior: SEER SSF: Human Papilloma Virus (HPV) Status
Answer N Percent
9 139 85.8 0 10 6.2
8 9 5.6
1 4 2.5
Total 162 100
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 64
Group 3-Brain
Group 3 Brain: Primary Site Answer N Percent
C714 165 96.5 C718 2 1.2
C719 2 1.2
C712 1 0.6
C713 1 0.6
Total 171 100
Group 3 Brain: Histology Answer N Percent
9440 168 98.2 8000 1 0.6
9442 1 0.6
9445 1 0.6
Total 171 100
Group 3 Brain: Tumor Size Clinical Answer N Percent
048 160 93.6
999 7 4.1
005 1 0.6
049 1 0.6
100 1 0.6
480 1 0.6
Total 171 100
Group 3 Brain: Tumor Size Pathologic Answer N Percent
999 156 91.2 100 7 4.1
048 3 1.8
020 2 1.2
055 1 0.6
Answer N Percent
480 1 0.6
998 1 0.6
Total 171 100
Group 3 Brain: EOD Primary Tumor Answer N Percent
100 156 91.2 999 10 5.8
500 4 2.3
050 1 0.6
Total 171 100
Group 3 Brain: EOD Regional Nodes Answer N Percent
888 171 100 Total 171 100
Group 3 Brain: Regional Nodes Positive Answer N Percent
99 145 84.8 98 13 7.6
00 11 6.4
88 2 1.2
Total 171 100
Group 3 Brain: EOD Mets Answer N Percent
00 166 97.1 99 5 2.9
Total 171 100
Group 3 Brain: SS2018 Answer N Percent
1 149 87.1
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 65
Answer N Percent
8 8 4.7
9 8 4.7
2 5 2.9
7 1 0.6
Total 171 100
Group 3 Brain: Grade Clinical Answer N Percent
9 133 77.8 H 23 13.5
4 15 8.8
Total 171 100
Group 3 Brain: Grade Pathological Answer N Percent
4 156 91.2 9 13 7.6
3 1 0.6
H 1 0.6
Total 171 100
Group 3 Brain: Grade Post Therapy Answer N Percent
BLANK 147 86 9 22 12.9
4 2 1.2
Total 171 100
Group 3 Brain: Brain Molecular Markers Answer N Percent
05 144 84.2 99 13 7.6
88 7 4.1
02 3 1.8
85 3 1.8
Answer N Percent
01 1 0.6
Total 171 100
Group 3 Brain: Chromosome 1p Status Answer N Percent
9 159 93 8 7 4.1
0 4 2.3
6 1 0.6
Total 171 100
Group 3 Brain: Chromosome 19q Status Answer N Percent
9 160 93.6 8 7 4.1
0 3 1.8
6 1 0.6
Total 171 100
Group 3 Brain: MGMT Answer N Percent
0 160 93.6 8 6 3.5
1 2 1.2
2 1 0.6
7 1 0.6
9 1 0.6
Total 171 100
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 66
Group 3-Breast
Group 3 Breast: Primary Site Answer N Percent
C501 123 71.1 C504 22 12.7
C508 14 8.1
C502 7 4
C509 4 2.3
C500 2 1.2
C505 1 0.6
Total 173 100
Group 3 Breast: Histology Answer N Percent
8500 172 99.4 8522 1 0.6
Total 173 100
Group 3 Breast: Behavior Answer N Percent
3 169 97.7 0 2 1.2
1 1 0.6
2 1 0.6
Total 173 100
Group 3 Breast: Tumor Size Clinical Answer N Percent
013 156 90.2 010 6 3.5
001 4 2.3
999 2 1.2
002 1 0.6
019 1 0.6
020 1 0.6
024 1 0.6
Answer N Percent
130 1 0.6
Total 173 100
Group 3 Breast: Tumor Size Pathologic Answer N Percent
027 167 96.5 030 2 1.2
001 1 0.6
003 1 0.6
004 1 0.6
270 1 0.6
Total 173 100
Group 3 Breast: EOD Primary Tumor Answer N Percent
100 167 96.5 000 3 1.7
050 1 0.6
200 1 0.6
999 1 0.6
Total 173 100
Group 3 Breast: EOD Regional Nodes Answer N Percent
000 109 63 070 62 35.8
050 1 0.6
999 1 0.6
Total 173 100
Group 3 Breast: Regional Nodes Positive Answer N Percent
00 167 96.5 98 6 3.5
Total 173 100
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 67
Group 3 Breast: EOD Mets Answer N Percent
00 170 98.3 05 2 1.2
99 1 0.6
Total 173 100
Group 3 Breast: SS2018 Answer N Percent
1 166 96 0 4 2.3
3 2 1.2
9 1 0.6
Total 173 100
Group 3 Breast: Grade Clinical Answer N Percent
3 152 87.9 1 6 3.5
9 5 2.9
H 5 2.9
C 2 1.2
2 1 0.6
B 1 0.6
M 1 0.6
Total 173 100
Group 3 Breast: Grade Pathological Answer N Percent
3 163 94.2 1 5 2.9
H 3 1.7
9 1 0.6
C 1 0.6
Total 173 100
Group 3 Breast: Grade Post Therapy Answer N Percent
BLANK 152 87.9 9 18 10.4
3 3 1.7
Total 173 100
Group 3 Breast: Sentinel Lymph Nodes Examined
Answer N Percent
04 162 93.6 98 3 1.7
01 2 1.2
03 2 1.2
95 2 1.2
00 1 0.6
02 1 0.6
Total 173 100
Group 3 Breast: Sentinel Lymph Nodes Positive Answer N Percent
00 172 99.4 04 1 0.6
Total 173 100
Group 3 Breast: ER Summary Answer N Percent
1 170 98.3 0 2 1.2
9 1 0.6
Total 173 100
Group 3 Breast: ER Percent Positive Answer N Percent
100 78 45.1 R99 43 24.9
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 68
Answer N Percent
099 28 16.2
XX9 10 5.8
097 3 1.7
XX7 3 1.7
000 2 1.2
R10 2 1.2
R90 2 1.2
096 1 0.6
XX8 1 0.6
Total 173 100
Group 3 Breast: ER Allred Score Answer N Percent
08 151 87.3 X9 9 5.2
07 8 4.6
00 1 0.6
02 1 0.6
03 1 0.6
05 1 0.6
X8 1 0.6
Total 173 100
Group 3 Breast: PR Summary Answer N Percent
1 171 98.8 0 1 0.6
9 1 0.6
Total 173 100
Group 3 Breast: PR Percent Positive Answer N Percent
063 90 52 R70 35 20.2
062 20 11.6
Answer N Percent
XX9 8 4.6
R99 5 2.9
XX7 4 2.3
R60 3 1.7
070 2 1.2
XX8 2 1.2
000 1 0.6
099 1 0.6
R10 1 0.6
R30 1 0.6
Total 173 100
Group 3 Breast: PR Allred Score Answer N Percent
07 148 85.5 08 12 6.9
X9 6 3.5
05 3 1.7
00 1 0.6
03 1 0.6
06 1 0.6
X8 1 0.6
Total 173 100
Group 3 Breast: HER2 IHC Summary Answer N Percent
2 139 80.3 3 17 9.8
0 9 5.2
1 6 3.5
8 1 0.6
9 1 0.6
Total 173 100
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 69
Group 3 Breast: HER2 ISH Summary Answer N Percent
3 123 71.1 2 20 11.6
9 18 10.4
0 11 6.4
8 1 0.6
Total 173 100
Group 3 Breast: HER2 ISH SP Copy No Answer N Percent
XX.9 126 72.8 6.1 14 8.1
2.4 7 4
2.5 7 4
XX.7 6 3.5
06.1 3 1.7
XX.8 2 1.2
0.0 1 0.6
2.0 1 0.6
24.0 1 0.6
25.0 1 0.6
48.6 1 0.6
80.0 1 0.6
99.9 1 0.6
XX.1 1 0.6
Total 173 100
Group 3 Breast: HER2 ISH DP Copy No Answer N Percent
XX.9 70 40.5 6.1 51 29.5
2.4 18 10.4
2.5 9 5.2
06.1 8 4.6
XX.7 5 2.9
Answer N Percent
XX.1 2 1.2
XX.8 2 1.2
0.0 1 0.6
1.0 1 0.6
24.0 1 0.6
25.0 1 0.6
3.7 1 0.6
80.0 1 0.6
99.6 1 0.6
99.9 1 0.6
Total 173 100
Group 3 Breast: HER2 ISH DP Ratio Answer N Percent
2.5 89 51.4 XX.9 35 20.2
XX.3 14 8.1
02.5 13 7.5
2.4 7 4
XX.2 3 1.7
XX.7 2 1.2
0.0 1 0.6
02.4 1 0.6
1.3 1 0.6
2.2 1 0.6
2.9 1 0.6
24.0 1 0.6
25.0 1 0.6
6.1 1 0.6
99.9 1 0.6
XX.8 1 0.6
Total 173 100
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 70
Group 3 Breast: Ki-67 (MIB-1) Answer N Percent
25.5 96 55.5 XXX.9 32 18.5
025.5 12 6.9
XXX.7 10 5.8
25.0 4 2.3
0.0 2 1.2
10.0 2 1.2
21.0 2 1.2
22.5 2 1.2
26.0 2 1.2
9.0 2 1.2
020.0 1 0.6
025.0 1 0.6
050.0 1 0.6
066.0 1 0.6
16.4 1 0.6
25.1 1 0.6
XXX.8 1 0.6
Total 173 100
Group 3 Breast: Lymph Nodes Positive Axillary Level I-III
Answer N Percent
00 159 91.9 X9 11 6.4
98 3 1.7
Total 173 100
Group 3 Breast: Multigene Signature Method Answer N Percent
9 161 93.1 8 5 2.9
5 3 1.7
1 2 1.2
Answer N Percent
6 2 1.2
Total 173 100
Group 3 Breast: Multigene Signature Results Answer N Percent
X9 161 93.1 X4 6 3.5
X8 3 1.7
00 1 0.6
99 1 0.6
X7 1 0.6
Total 173 100
Group 3 Breast: Oncotype DX Recur Score-DCIS Answer N Percent
XX6 113 65.3 XX9 47 27.2
XX8 5 2.9
XX7 4 2.3
000 2 1.2
002 1 0.6
009 1 0.6
Total 173 100
Group 3 Breast: Oncotype DX Recur Score Answer N Percent
XX9 89 51.4 XX7 77 44.5
XX6 3 1.7
000 2 1.2
XX5 2 1.2
Total 173 100
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 71
Group 3 Breast: Oncotype DX Risk Level-DCIS Answer N Percent
6 111 64.2 9 51 29.5
8 6 3.5
2 3 1.7
0 2 1.2
Total 173 100
Group 3 Breast: Oncotype DX Risk Level Invasive
Answer N Percent
2 88 50.9 9 76 43.9
7 6 3.5
0 1 0.6
6 1 0.6
8 1 0.6
Total 173 100
Group 3 Breast: Response Neoadjuv Therapy Answer N Percent
0 149 86.1 9 21 12.1
3 2 1.2
8 1 0.6
Total 173 100
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 72
Group 3-Colon and Rectum
Group 3 Colon and Rectum: Primary Site Answer N Percent
C187 109 64.1 C199 60 35.3
C189 1 0.6
Total 170 100
Group 3 Colon and Rectum: Histology Answer N Percent
8140 148 87.1 8263 18 10.6
8210 3 1.8
8261 1 0.6
Total 170 100
Group 3 Colon and Rectum: Behavior Answer N Percent
3 167 98.2 2 2 1.2
0 1 0.6
Total 170 100
Group 3 Colon and Rectum: Tumor Size Clinical Answer N Percent
999 99 58.2 060 65 38.2
089 2 1.2
000 1 0.6
018 1 0.6
180 1 0.6
600 1 0.6
Total 170 100
Group 3 Colon and Rectum: Tumor Size Pathologic
Answer N Percent
089 167 98.2 090 2 1.2
890 1 0.6
Total 170 100
Group 3 Colon and Rectum: EOD Primary Tumor
Answer N Percent
300 87 51.2 400 73 42.9
200 6 3.5
100 2 1.2
999 2 1.2
Total 170 100
Group 3 Colon and Rectum: EOD Regional Nodes
Answer N Percent
000 169 99.4 300 1 0.6
Total 170 100
Group 3 Colon and Rectum: Regional Nodes Positive
Answer N Percent
00 169 99.4 38 1 0.6
Total 170 100
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 73
Group 3 Colon and Rectum: EOD Mets Answer N Percent
00 169 99.4 20 1 0.6
Total 170 100
Group 3 Colon and Rectum: SS2018 Answer N Percent
2 91 53.5 1 78 45.9
9 1 0.6
Total 170 100
Group 3 Colon and Rectum: Grade Clinical Answer N Percent
9 159 93.5 2 10 5.9
4 1 0.6
Total 170 100
Group 3 Colon and Rectum: Grade Pathological Answer N Percent
2 166 97.6 1 3 1.8
3 1 0.6
Total 170 100
Group 3 Colon and Rectum: Grade Post Therapy
Answer N Percent
BLANK 150 88.2 9 18 10.6
2 2 1.2
Total 170 100
Group 3 Colon and Rectum: CEA PreTX Interpretation
Answer N Percent
9 164 96.5 8 3 1.8
0 2 1.2
3 1 0.6
Total 170 100
Group 3 Colon and Rectum: CEA PreTX Lab Value
Answer N Percent
XXXX.9 163 95.9 9999.9 2 1.2
XXXX.8 2 1.2
0.0 1 0.6
0000.9 1 0.6
999.9 1 0.6
Total 170 100
Group 3 Colon and Rectum: Circumferential Resection Margin
Answer N Percent
XX.1 154 90.6 XX.9 8 4.7
0.0 2 1.2
00.1 2 1.2
03.5 1 0.6
3.0 1 0.6
7.0 1 0.6
99.9 1 0.6
Total 170 100
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 74
Group 3 Colon and Rectum: KRAS Answer N Percent
9 166 97.6 8 3 1.8
0 1 0.6
Total 170 100
Group 3 Colon and Rectum: Microsatellite Instability
Answer N Percent
0 107 62.9 9 34 20
2 23 13.5
1 6 3.5
Total 170 100
Group 3 Colon and Rectum: Perineural Invasion
Answer N Percent
0 167 98.2 9 3 1.8
Total 170 100
Group 3 Colon and Rectum: Tumor Deposits Answer N Percent
00 165 97.1 X9 5 2.9
Total 170 100
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 75
Group 3-Lung
Group 3 Lung: Primary Site Answer N Percent
C341 163 98.2 C343 3 1.8
Total 166 100
Group 3 Lung: Histology Answer N Percent
8140 114 68.7 8230 51 30.7
8150 1 0.6
Total 166 100
Group 3 Lung: Behavior Answer N Percent
3 166 100 Total 166 100
Group 3 Lung: Tumor Size Clinical Answer N Percent
043 136 81.9 045 26 15.7
040 2 1.2
035 1 0.6
430 1 0.6
Total 166 100
Group 3 Lung: Tumor Size Pathologic Answer N Percent
035 164 98.8 040 1 0.6
350 1 0.6
Total 166 100
Group 3 Lung: EOD Primary Tumor Answer N Percent
450 114 68.7 300 38 22.9
100 5 3
400 4 2.4
200 3 1.8
999 2 1.2
Total 166 100
Group 3 Lung: EOD Regional Nodes Answer N Percent
300 140 84.3 400 16 9.6
700 3 1.8
000 2 1.2
600 2 1.2
800 2 1.2
999 1 0.6
Total 166 100
Group 3 Lung: Regional Nodes Positive Answer N Percent
01 163 98.2 00 2 1.2
02 1 0.6
Total 166 100
Group 3 Lung: EOD Mets Answer N Percent
00 163 98.2 10 1 0.6
20 1 0.6
99 1 0.6
Total 166 100
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 76
Group 3 Lung: SS2018 Answer N Percent
4 92 55.4 3 44 26.5
2 17 10.2
1 12 7.2
9 1 0.6
Total 166 100
Group 3 Lung: Grade Clinical Answer N Percent
9 153 92.2 3 11 6.6
1 2 1.2
Total 166 100
Group 3 Lung: Grade Pathological Answer N Percent
3 160 96.4 1 2 1.2
2 2 1.2
4 1 0.6
9 1 0.6
Total 166 100
Group 3 Lung: Grade Post Therapy Answer N Percent
BLANK 148 89.2 9 16 9.6
3 2 1.2
Total 166 100
Group 3 Lung: Separate Tumor Nodules Answer N Percent
0 160 96.4 9 4 2.4
1 1 0.6
8 1 0.6
Total 166 100
Group 3 Lung: Visceral and Parietal Pleural Invasion
Answer N Percent
4 96 57.8 1 42 25.3
0 13 7.8
2 5 3
3 5 3
6 3 1.8
9 2 1.2
Total 166 100
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 77
Group 3-Lymphoma (CLL/SLL)
Group 3 Lymphoma (CLL/SLL): Primary Site Answer N Percent
C421 155 95.7 C779 5 3.1
C775 1 0.6
C809 1 0.6
Total 162 100
Group 3 Lymphoma (CLL/SLL): Histology Answer N Percent
9823 162 100 Total 162 100
Group 3 Lymphoma (CLL/SLL): Behavior Answer N Percent
3 159 98.1 2 2 1.2
0 1 0.6
Total 162 100
Group 3 Lymphoma (CLL/SLL): Tumor Size Clinical
Answer N Percent
999 158 97.5 988 3 1.9
888 1 0.6
Total 162 100
Group 3 Lymphoma (CLL/SLL): Tumor Size Pathologic
Answer N Percent
999 158 97.5 988 3 1.9
888 1 0.6
Answer N Percent
Total 162 100
Group 3 Lymphoma (CLL/SLL): EOD Primary Tumor
Answer N Percent
800 128 79 999 20 12.3
700 7 4.3
200 4 2.5
100 3 1.9
Total 162 100
Group 3 Lymphoma (CLL/SLL): EOD Regional Nodes
Answer N Percent
888 162 100 Total 162 100
Group 3 Lymphoma (CLL/SLL): Regional Nodes Positive
Answer N Percent
99 153 94.4 98 4 2.5
00 3 1.9
88 2 1.2
Total 162 100
Group 3 Lymphoma (CLL/SLL): EOD Mets Answer N Percent
88 162 100 Total 162 100
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 78
Group 3 Lymphoma (CLL/SLL): SS2018 Answer N Percent
7 135 83.3 9 18 11.1
1 9 5.6
Total 162 100
Group 3 Lymphoma (CLL/SLL): Grade Clinical Answer N Percent
8 162 100 Total 162 100
Group 3 Lymphoma (CLL/SLL): Grade Pathological
Answer N Percent
8 162 100 Total 162 100
Group 3 Lymphoma (CLL/SLL): Grade Post Therapy
Answer N Percent
BLANK 112 69.1 8 50 30.9
Total 162 100
Group 3 Lymphoma (CLL/SLL): Adenopathy Answer N Percent
0 105 64.8 9 29 17.9
1 28 17.3
Total 162 100
Group 3 Lymphoma (CLL/SLL): Anemia Answer N Percent
0 105 64.8 9 29 17.9
Answer N Percent
1 28 17.3
Total 162 100
Group 3 Lymphoma (CLL/SLL): B Symptoms Answer N Percent
0 109 67.3 9 51 31.5
1 2 1.2
Total 162 100
Group 3 Lymphoma (CLL/SLL): HIV Status Answer N Percent
9 138 85.2 0 24 14.8
Total 162 100
Group 3 Lymphoma (CLL/SLL): NCCN International Prognostic Index (IPI)
Answer N Percent
X9 158 97.5 X8 2 1.2
00 1 0.6
X3 1 0.6
Total 162 100
Group 3 Lymphoma (CLL/SLL): Organomegaly Answer N Percent
9 104 64.2 0 58 35.8
Total 162 100
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 79
Group 3 Lymphoma (CLL/SLL): Thrombocytopenia
Answer N Percent
0 93 57.4 9 39 24.1
1 29 17.9
7 1 0.6
Total 162 100
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 80
Group 3-Melanoma Skin
Group 3 Melanoma Skin: Primary Site Answer N Percent
C446 161 98.2 C443 1 0.6
C447 1 0.6
C449 1 0.6
Total 164 100
Group 3 Melanoma Skin: Histology Answer N Percent
8720 137 83.5 8771 24 14.6
8744 3 1.8
Total 164 100
Group 3 Melanoma Skin: Behavior Answer N Percent
3 163 99.4 1 1 0.6
Total 164 100
Group 3 Melanoma Skin: Tumor Size Clinical Answer N Percent
999 131 79.9 001 16 9.8
008 14 8.5
004 1 0.6
010 1 0.6
100 1 0.6
Total 164 100
Group 3 Melanoma Skin: Tumor Size Pathologic
Answer N Percent
999 126 76.8 000 13 7.9
001 11 6.7
008 5 3
004 3 1.8
006 1 0.6
010 1 0.6
012 1 0.6
013 1 0.6
025 1 0.6
100 1 0.6
Total 164 100
Group 3 Melanoma Skin: EOD Primary Tumor Answer N Percent
300 144 87.8 100 10 6.1
400 3 1.8
999 3 1.8
200 2 1.2
000 1 0.6
500 1 0.6
Total 164 100
Group 3 Melanoma Skin: EOD Regional Nodes Answer N Percent
000 163 99.4 999 1 0.6
Total 164 100
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 81
Group 3 Melanoma Skin: Regional Nodes Positive
Answer N Percent
00 153 93.3 98 8 4.9
99 3 1.8
Total 164 100
Group 3 Melanoma Skin: EOD Mets Answer N Percent
00 164 100 Total 164 100
Group 3 Melanoma Skin: SS2018 Answer N Percent
1 159 97 2 2 1.2
9 2 1.2
0 1 0.6
Total 164 100
Group 3 Melanoma Skin: Grade Clinical Answer N Percent
9 163 99.4 C 1 0.6
Total 164 100
Group 3 Melanoma Skin: Grade Pathological Answer N Percent
9 163 99.4 C 1 0.6
Total 164 100
Group 3 Melanoma Skin: Grade Post Therapy Answer N Percent
BLANK 146 89
Answer N Percent
9 18 11
Total 164 100
Group 3 Melanoma Skin: Sentinel Lymph Nodes Examined
Answer N Percent
02 157 95.7 00 4 2.4
01 2 1.2
04 1 0.6
Total 164 100
Group 3 Melanoma Skin: Sentinel Lymph Nodes Positive
Answer N Percent
00 161 98.2 02 3 1.8
Total 164 100
Group 3 Melanoma Skin: Breslow Thickness Answer N Percent
1.0 128 78 0.1 14 8.5
01.0 8 4.9
XX.1 4 2.4
XX.9 3 1.8
0.0 1 0.6
0.5 1 0.6
0.6 1 0.6
01.1 1 0.6
10.0 1 0.6
A0.1 1 0.6
A1.0 1 0.6
Total 164 100
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 82
Group 3 Melanoma Skin: Ulceration Answer N Percent
0 155 94.5 9 7 4.3
1 2 1.2
Total 164 100
Group 3 Melanoma Skin: LDH (Lactate Dehydrogenase) Pretreatment Lab Value
Answer N Percent
XXXXX.9 155 94.5 XXXXX.7 5 3
99999.9 2 1.2
0.0 1 0.6
XXXXX.8 1 0.6
Total 164 100
Group 3 Melanoma Skin: LDH (Lactate Dehydrogenase) Pretreatment Level
Answer N Percent
9 157 95.7 7 5 3
0 1 0.6
1 1 0.6
Total 164 100
Group 3 Melanoma Skin: LDH Upper Limits Normal
Answer N Percent
XX9 157 95.7 999 4 2.4
001 1 0.6
998 1 0.6
XX8 1 0.6
Total 164 100
Group 3 Melanoma Skin: Mitotic Rate Melanoma
Answer N Percent
05 154 93.9 X9 8 4.9
00 2 1.2
Total 164 100
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 83
Group 3-Ovary
Group 3 Ovary: Primary Site Answer N Percent
C569 164 100 Total 164 100
Group 3 Ovary: Histology Answer N Percent
8441 131 79.9 8461 29 17.7
8144 1 0.6
8323 1 0.6
8460 1 0.6
8462 1 0.6
Total 164 100
Group 3 Ovary: Behavior Answer N Percent
3 164 100 Total 164 100
Group 3 Ovary: Tumor Size Clinical Answer N Percent
144 93 56.7 140 45 27.4
014 13 7.9
104 6 3.7
999 3 1.8
087 2 1.2
989 2 1.2
Total 164 100
Group 3 Ovary: Tumor Size Pathologic Answer N Percent
140 119 72.6
Answer N Percent
999 22 13.4
014 11 6.7
144 6 3.7
989 2 1.2
011 1 0.6
104 1 0.6
110 1 0.6
145 1 0.6
Total 164 100
Group 3 Ovary: EOD Primary Tumor Answer N Percent
300 120 73.2 400 26 15.9
200 3 1.8
250 3 1.8
450 3 1.8
100 2 1.2
999 2 1.2
150 1 0.6
350 1 0.6
500 1 0.6
600 1 0.6
750 1 0.6
Total 164 100
Group 3 Ovary: EOD Regional Nodes Answer N Percent
000 162 98.8 050 1 0.6
800 1 0.6
Total 164 100
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 84
Group 3 Ovary: Regional Nodes Positive Answer N Percent
00 164 100 Total 164 100
Group 3 Ovary: EOD Mets Answer N Percent
00 162 98.8 70 1 0.6
99 1 0.6
Total 164 100
Group 3 Ovary: SS2018 Answer N Percent
2 141 86 1 17 10.4
3 2 1.2
9 2 1.2
4 1 0.6
7 1 0.6
Total 164 100
Group 3 Ovary: Grade Clinical Answer N Percent
9 147 89.6 H 17 10.4
Total 164 100
Group 3 Ovary: Grade Pathological Answer N Percent
H 156 95.1 3 6 3.7
9 2 1.2
Total 164 100
Group 3 Ovary: Grade Post Therapy Answer N Percent
BLANK 144 87.8 9 16 9.8
1 1 0.6
3 1 0.6
B 1 0.6
H 1 0.6
Total 164 100
Group 3 Ovary: CA-125 PreTX Lab Value Answer N Percent
1 150 91.5 9 10 6.1
2 4 2.4
Total 164 100
Group 3 Ovary: FIGO Stage Answer N Percent
11 108 65.9 99 46 28
21 2 1.2
98 2 1.2
01 1 0.6
05 1 0.6
08 1 0.6
10 1 0.6
20 1 0.6
31 1 0.6
Total 164 100
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 85
Group 3 Ovary: Residual Tumor Volume Post Cytoreduction
Answer N Percent
97 82 50 00 50 30.5
99 27 16.5
98 2 1.2
10 1 0.6
30 1 0.6
93 1 0.6
Total 164 100
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 86
Group 3-Prostate
Group 3 Prostate: Primary Site Answer N Percent
C619 167 100 Total 167 100
Group 3 Prostate: Histology Answer N Percent
8140 157 94 8550 10 6
Total 167 100
Group 3 Prostate: Behavior Answer N Percent
3 166 99.4 0 1 0.6
Total 167 100
Group 3 Prostate: Tumor Size Clinical Answer N Percent
999 152 91 010 11 6.6
000 2 1.2
001 1 0.6
002 1 0.6
Total 167 100
Group 3 Prostate: Tumor Size Pathologic Answer N Percent
999 144 86.2 012 15 9
010 3 1.8
000 2 1.2
049 1 0.6
120 1 0.6
Answer N Percent
320 1 0.6
Total 167 100
Group 3 Prostate: EOD Primary Tumor Answer N Percent
120 51 30.5 200 34 20.4
220 25 15
300 21 12.6
250 16 9.6
150 8 4.8
100 3 1.8
210 3 1.8
999 3 1.8
000 1 0.6
110 1 0.6
400 1 0.6
Total 167 100
Group 3 Prostate: EOD Regional Nodes Answer N Percent
000 161 96.4 300 3 1.8
999 3 1.8
Total 167 100
Group 3 Prostate: Regional Node Positive Answer N Percent
00 158 94.6 98 7 4.2
05 1 0.6
99 1 0.6
Total 167 100
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 87
Group 3 Prostate: EOD Mets Answer N Percent
00 164 98.2 99 3 1.8
Total 167 100
Group 3 Prostate: SS2018 Answer N Percent
1 158 94.6 9 4 2.4
2 3 1.8
0 1 0.6
3 1 0.6
Total 167 100
Group 3 Prostate: Grade Clinical Answer N Percent
4 158 94.6 3 5 3
1 2 1.2
9 2 1.2
Total 167 100
Group 3 Prostate: Grade Pathological Answer N Percent
3 80 47.9 4 53 31.7
9 31 18.6
2 2 1.2
1 1 0.6
Total 167 100
Group 3 Prostate: Grade Post Therapy Answer N Percent
BLANK 123 73.7 3 23 13.8
Answer N Percent
9 15 9
4 3 1.8
2 2 1.2
5 1 0.6
Total 167 100
Group 3 Prostate: PSA Lab Value Answer N Percent
4.0 108 64.7 4.4 40 24
004.0 6 3.6
0.4 4 2.4
XXX.9 4 2.4
04.0 2 1.2
04.4 2 1.2
4.7 1 0.6
Total 167 100
Group 3 Prostate: Gleason Patterns Clinical Answer N Percent
35 156 93.4 44 2 1.2
53 2 1.2
11 1 0.6
33 1 0.6
34 1 0.6
39 1 0.6
43 1 0.6
X6 1 0.6
X8 1 0.6
Total 167 100
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 88
Group 3 Prostate: Gleason Score Clinical Answer N Percent
08 164 98.2 03 1 0.6
06 1 0.6
09 1 0.6
Total 167 100
Group 3 Prostate: Gleason Patterns Pathological
Answer N Percent
43 129 77.2 X9 14 8.4
35 13 7.8
X7 6 3.6
X8 2 1.2
11 1 0.6
34 1 0.6
X6 1 0.6
Total 167 100
Group 3 Prostate: Gleason Score Pathological Answer N Percent
07 127 76 X9 16 9.6
08 15 9
X7 6 3.6
03 2 1.2
X8 1 0.6
Total 167 100
Group 3 Prostate: Gleason Tertiary Pattern Answer N Percent
50 130 77.8 X9 27 16.2
X7 6 3.6
Answer N Percent
X8 3 1.8
10 1 0.6
Total 167 100
Group 3 Prostate: Number of Cores Examined Answer N Percent
12 98 58.7 26 17 10.2
05 15 9
08 14 8.4
11 6 3.6
X6 6 3.6
06 5 3
07 1 0.6
13 1 0.6
24 1 0.6
X7 1 0.6
X8 1 0.6
X9 1 0.6
Total 167 100
Group 3 Prostate: Number of Cores Positive Answer N Percent
05 132 79 03 11 6.6
12 11 6.6
08 5 3
00 3 1.8
04 1 0.6
11 1 0.6
X6 1 0.6
X8 1 0.6
X9 1 0.6
Total 167 100
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 89
Group 3-Soft Tissue Abdomen and Thoracic
Group 3 Soft Tissue: Primary Site Answer N Percent
C493 161 98.2 C495 2 1.2
C473 1 0.6
Total 164 100
Group 3 Soft Tissue: Histology Answer N Percent
8801 131 79.9 8825 9 5.5
8810 7 4.3
8857 7 4.3
8032 2 1.2
8811 2 1.2
9041 2 1.2
8004 1 0.6
8772 1 0.6
8815 1 0.6
8912 1 0.6
Total 164 100
Group 3 Soft Tissue: Behavior Answer N Percent
3 164 100 Total 164 100
Group 3 Soft Tissue: Tumor Size Clinical Answer N Percent
036 139 84.8 999 12 7.3
025 6 3.7
360 3 1.8
015 2 1.2
037 1 0.6
Answer N Percent
100 1 0.6
Total 164 100
Group 3 Soft Tissue: Tumor Size Pathologic Answer N Percent
025 154 93.9 250 3 1.8
999 2 1.2
000 1 0.6
030 1 0.6
036 1 0.6
120 1 0.6
130 1 0.6
Total 164 100
Group 3 Soft Tissue: EOD Primary Tumor Answer N Percent
100 124 75.6 400 18 11
500 8 4.9
200 7 4.3
999 4 2.4
300 3 1.8
Total 164 100
Group 3 Soft Tissue: EOD Regional Nodes Answer N Percent
000 139 84.8 999 25 15.2
Total 164 100
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 90
Group 3 Soft Tissue: Regional Nodes Positive Answer N Percent
98 116 70.7 00 41 25
99 7 4.3
Total 164 100
Group 3 Soft Tissue: EOD Mets Answer N Percent
00 163 99.4 99 1 0.6
Total 164 100
Group 3 Soft Tissue: SS2018 Answer N Percent
1 133 81.1 2 27 16.5
9 3 1.8
3 1 0.6
Total 164 100
Group 3 Soft Tissue: Grade Clinical Answer N Percent
9 137 83.5 2 12 7.3
1 10 6.1
B 3 1.8
3 2 1.2
Total 164 100
Group 3 Soft Tissue: Grade Pathological Answer N Percent
1 46 28 3 46 28
2 42 25.6
9 19 11.6
Answer N Percent
B 10 6.1
A 1 0.6
Total 164 100
Group 3 Soft Tissue: Grade Post Therapy Answer N Percent
BLANK 128 78 9 30 18.3
1 2 1.2
2 2 1.2
3 1 0.6
B 1 0.6
Total 164 100
Group 3 Soft Tissue: Bone Invasion Answer N Percent
0 156 95.1 1 4 2.4
9 4 2.4
Total 164 100
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 91
Group 3-Tongue Anterior
Group 3 Tongue Anterior: Primary Site Answer N Percent
C020 94 57.7 C022 47 28.8
C023 10 6.1
C029 8 4.9
C028 4 2.5
Total 163 100
Group 3 Tongue Anterior: Histology Answer N Percent
8070 155 95.1 8075 6 3.7
8084 1 0.6
8270 1 0.6
Total 163 100
Group 3 Tongue Anterior: Behavior Answer N Percent
3 162 99.4 2 1 0.6
Total 163 100
Group 3 Tongue Anterior: Tumor Size Clinical Answer N Percent
024 113 69.3 030 32 19.6
025 9 5.5
999 9 5.5
Total 163 100
Group 3 Tongue Anterior: Tumor Size Pathologic
Answer N Percent
025 160 98.2
Answer N Percent
008 1 0.6
024 1 0.6
026 1 0.6
Total 163 100
Group 3 Tongue Anterior: EOD Primary Tumor Answer N Percent
150 107 65.6 400 29 17.8
100 14 8.6
200 4 2.5
999 4 2.5
500 3 1.8
300 2 1.2
Total 163 100
Group 3 Tongue Anterior: EOD Regional Nodes Answer N Percent
600 102 62.6 250 29 17.8
150 15 9.2
200 5 3.1
800 4 2.5
500 3 1.8
100 2 1.2
000 1 0.6
400 1 0.6
999 1 0.6
Total 163 100
Group 3 Tongue Anterior: Regional Nodes Positive
Answer N Percent
02 161 98.8 01 2 1.2
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 92
Answer N Percent
Total 163 100
Group 3 Tongue Anterior: EOD Mets Answer N Percent
00 161 98.8 99 2 1.2
Total 163 100
Group 3 Tongue Anterior: SS2018 Answer N Percent
3 111 68.1 4 33 20.2
1 13 8
2 4 2.5
9 2 1.2
Total 163 100
Group 3 Tongue Anterior: Grade Clinical Answer N Percent
3 142 87.1 9 19 11.7
2 2 1.2
Total 163 100
Group 3 Tongue Anterior: Grade Pathological Answer N Percent
2 102 62.6 3 59 36.2
1 1 0.6
9 1 0.6
Total 163 100
Group 3 Tongue Anterior: Grade Post Therapy Answer N Percent
BLANK 146 89.6 9 15 9.2
2 1 0.6
3 1 0.6
Total 163 100
Group 3 Tongue Anterior: Extranodal Exten H&N Clin
Answer N Percent
0 84 51.5 9 29 17.8
7 28 17.2
1 13 8
2 7 4.3
8 2 1.2
Total 163 100
Group 3 Tongue Anterior: Extranodal Exten H&N Path
Answer N Percent
X.2 89 54.6 0.2 21 12.9
2.0 19 11.7
X.4 8 4.9
0.4 7 4.3
0.0 4 2.5
0.1 4 2.5
1.9 4 2.5
X.1 2 1.2
X.8 2 1.2
4.0 1 0.6
8.0 1 0.6
9.9 1 0.6
Total 163 100
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 93
Group 3 Tongue Anterior: LN Size Answer N Percent
0.4 66 40.5 4.0 52 31.9
04.0 10 6.1
00.4 8 4.9
XX.3 6 3.7
XX.9 6 3.7
10.0 4 2.5
0.7 2 1.2
XX.6 2 1.2
0.0 1 0.6
0.1 1 0.6
07.0 1 0.6
40.0 1 0.6
XX.1 1 0.6
XX.2 1 0.6
XX.4 1 0.6
Total 163 100
Group 3 Tongue Anterior: SEER SSF: Human Papilloma Virus (HPV) Status
Answer N Percent
9 152 93.3 0 11 6.7
Total 163 100
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 94
Group 4-Brain
Group 4 Brain: Primary Site Answer N Percent
C713 103 62.4 C718 38 23
C714 16 9.7
C710 3 1.8
C712 2 1.2
C719 2 1.2
C715 1 0.6
Total 165 100
Group 4 Brain: Histology Answer N Percent
9440 160 97 9400 3 1.8
8720 1 0.6
9445 1 0.6
Total 165 100
Group 4 Brain: Behavior Answer N Percent
3 165 100 Total 165 100
Group 4 Brain: Tumor Size Clinical Answer N Percent
075 147 89.1 999 8 4.8
750 4 2.4
008 2 1.2
030 2 1.2
070 1 0.6
074 1 0.6
Total 165 100
Group 4 Brain: Tumor Size Pathologic Answer N Percent
999 154 93.3 080 6 3.6
075 2 1.2
001 1 0.6
008 1 0.6
989 1 0.6
Total 165 100
Group 4 Brain: EOD Primary Tumor Answer N Percent
100 139 84.2 500 13 7.9
999 12 7.3
700 1 0.6
Total 165 100
Group 4 Brain: EOD Regional Nodes Answer N Percent
888 165 100 Total 165 100
Group 4 Brain: Regional Nodes Positive Answer N Percent
99 136 82.4 00 16 9.7
98 12 7.3
88 1 0.6
Total 165 100
Group 4 Brain: EOD Mets Answer N Percent
00 161 97.6 99 3 1.8
10 1 0.6
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 95
Answer N Percent
Total 165 100
Group 4 Brain: SS2018 Answer N Percent
1 144 87.3 2 11 6.7
9 6 3.6
8 3 1.8
7 1 0.6
Total 165 100
Group 4 Brain: Grade Clinical Answer N Percent
9 128 77.6 4 35 21.2
3 1 0.6
H 1 0.6
Total 165 100
Group 4 Brain: Grade Pathological Answer N Percent
4 143 86.7 9 18 10.9
H 2 1.2
3 1 0.6
D 1 0.6
Total 165 100
Group 4 Brain: Grade Post Therapy Answer N Percent
BLANK 123 74.5 9 36 21.8
4 5 3
1 1 0.6
Total 165 100
Group 4 Brain: Brain Molecular Markers Answer N Percent
05 132 80 99 14 8.5
88 6 3.6
01 3 1.8
02 3 1.8
04 3 1.8
85 3 1.8
09 1 0.6
Total 165 100
Group 4 Brain: Chromosome 1p Status Answer N Percent
9 154 93.3 8 9 5.5
0 1 0.6
1 1 0.6
Total 165 100
Group 4 Brain: Chromosome 19q Status Answer N Percent
9 155 93.9 8 9 5.5
0 1 0.6
Total 165 100
Group 4 Brain: MGMT Answer N Percent
9 153 92.7 8 10 6.1
0 1 0.6
1 1 0.6
Total 165 100
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 96
Group 4-Breast
Group 4 Breast: Primary Site Answer N Percent
C508 149 90.9 C509 7 4.3
C504 4 2.4
C502 3 1.8
C505 1 0.6
Total 164 100
Group 4 Breast: Histology Answer N Percent
8520 148 90.2 8522 11 6.7
8500 2 1.2
8502 1 0.6
8519 1 0.6
8523 1 0.6
Total 164 100
Group 4 Breast: Behavior Answer N Percent
3 161 98.2 2 3 1.8
Total 164 100
Group 4 Breast: Tumor Size Clinical Answer N Percent
028 85 51.8 030 42 25.6
025 21 12.8
040 11 6.7
003 1 0.6
023 1 0.6
026 1 0.6
050 1 0.6
Answer N Percent
280 1 0.6
Total 164 100
Group 4 Breast: Tumor Size Pathologic Answer N Percent
035 158 96.3 004 2 1.2
350 2 1.2
999 2 1.2
Group 4 Breast: EOD Primary Tumor Answer N Percent
100 155 94.5 000 2 1.2
200 2 1.2
300 2 1.2
999 2 1.2
070 1 0.6
Total 164 100
Group 4 Breast: EOD Regional Nodes Answer N Percent
000 100 61 070 62 37.8
030 1 0.6
999 1 0.6
Total 164 100
Group 4 Breast: Regional Nodes Positive Answer N Percent
00 157 95.7 98 5 3
05 1 0.6
99 1 0.6
Total 164 100
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 97
Group 4 Breast: EOD Mets Answer N Percent
00 160 97.6 05 3 1.8
99 1 0.6
Total 164 100
Group 4 Breast: SS2018 Answer N Percent
1 156 95.1 0 4 2.4
9 3 1.8
2 1 0.6
Total 164 100
Group 4 Breast: Grade Clinical Answer N Percent
2 125 76.2 9 21 12.8
3 9 5.5
B 5 3
1 3 1.8
M 1 0.6
Total 164 100
Group 4 Breast: Grade Pathological Answer N Percent
3 154 93.9 2 5 3
1 3 1.8
9 2 1.2
Total 164 100
Group 4 Breast: Grade Post Therapy Answer N Percent
BLANK 134 81.7
Answer N Percent
9 30 18.3
Total 164 100
Group 4 Breast: Sentinel Lymph Nodes Examined
Answer N Percent
05 157 95.7 04 2 1.2
00 1 0.6
03 1 0.6
06 1 0.6
10 1 0.6
99 1 0.6
Total 164 100
Group 4 Breast: Sentinel Lymph Nodes Positive Answer N Percent
00 161 98.2 05 1 0.6
98 1 0.6
99 1 0.6
Total 164 100
Group 4 Breast: ER Summary Answer N Percent
1 160 97.6 0 3 1.8
9 1 0.6
Total 164 100
Group 4 Breast: ER Percent Positive Answer N Percent
R99 135 82.3 XX9 7 4.3
100 6 3.7
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 98
Answer N Percent
008 4 2.4
091 4 2.4
083 3 1.8
R10 2 1.2
085 1 0.6
095 1 0.6
XX7 1 0.6
Total 164 100
Group 4 Breast: ER Allred Score Answer N Percent
08 81 49.4 X9 74 45.1
02 2 1.2
07 2 1.2
00 1 0.6
01 1 0.6
03 1 0.6
04 1 0.6
X8 1 0.6
Total 164 100
Group 4 Breast: PR Summary Answer N Percent
1 158 96.3 0 3 1.8
9 2 1.2
7 1 0.6
Total 164 100
Group 4 Breast: PR Percent Positive Answer N Percent
R99 130 79.3 XX9 9 5.5
100 6 3.7
Answer N Percent
091 5 3
008 4 2.4
079 3 1.8
XX7 2 1.2
010 1 0.6
080 1 0.6
R40 1 0.6
R70 1 0.6
XX8 1 0.6
Total 164 100
Group 4 Breast: PR Allred Score Answer N Percent
X9 77 47 08 75 45.7
07 3 1.8
X8 3 1.8
02 2 1.2
00 1 0.6
01 1 0.6
03 1 0.6
04 1 0.6
Total 164 100
Group 4 Breast: HER2 IHC Summary Answer N Percent
1 118 72 0 36 22
9 7 4.3
4 2 1.2
2 1 0.6
Total 164 100
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 99
Group 4 Breast: HER2 ISH Summary Answer N Percent
9 133 81.1 0 24 14.6
8 7 4.3
Total 164 100
Group 4 Breast: HER2 Overall Summary Answer N Percent
0 143 87.2 9 11 6.7
1 10 6.1
Total 164 100
Group 4 Breast: HER2 ISH SP Copy No Answer N Percent
XX.9 149 90.9 XX.8 8 4.9
8.2 3 1.8
08.2 1 0.6
99.8 1 0.6
XX.1 1 0.6
XX.7 1 0.6
Total 164 100
Group 4 Breast: HER2 ISH DP Copy No Answer N Percent
XX.9 153 93.3 XX.8 6 3.7
8.2 2 1.2
08.2 1 0.6
99.8 1 0.6
XX.7 1 0.6
Total 164 100
Group 4 Breast: HER2 ISH DP Ratio Answer N Percent
XX.9 154 93.9 XX.8 6 3.7
8.2 2 1.2
99.8 1 0.6
XX.7 1 0.6
Total 164 100
Group 4 Breast: Ki-67 (MIB-1) Answer N Percent
0.4 53 32.3 XXX.9 27 16.5
38.0 23 14
XXX.7 22 13.4
0.3 13 7.9
000.4 8 4.9
3.8 6 3.7
00.4 4 2.4
038.0 2 1.2
XXX.8 2 1.2
0.0 1 0.6
00.3 1 0.6
100.0 1 0.6
8.2 1 0.6
Total 164 100
Group 4 Breast: Lymph Nodes Positive Axillary Level I-III
Answer N Percent
00 143 87.2 X9 17 10.4
99 2 1.2
98 1 0.6
X8 1 0.6
Total 164 100
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 100
Group 4 Breast: Multigene Signature Method Answer N Percent
9 141 86 8 12 7.3
5 5 3
1 2 1.2
3 2 1.2
6 1 0.6
7 1 0.6
Total 164 100
Group 4 Breast: Multigene Signature Result Answer N Percent
X9 136 82.9 X8 10 6.1
X3 5 3
25 4 2.4
21 2 1.2
99 2 1.2
00 1 0.6
09 1 0.6
88 1 0.6
X2 1 0.6
X4 1 0.6
Total 164 100
Group 4 Breast: Oncotype DX Recur Score-DCIS Answer N Percent
XX6 113 68.9 XX9 39 23.8
025 6 3.7
XX8 4 2.4
006 1 0.6
083 1 0.6
Total 164 100
Group 4 Breast: Oncotype DX Recur Score Answer N Percent
025 142 86.6 XX5 9 5.5
XX9 9 5.5
000 1 0.6
008 1 0.6
026 1 0.6
XX4 1 0.6
Total 164 100
Group 4 Breast: Oncotype DX Risk Level-DCIS Answer N Percent
6 106 64.6 9 45 27.4
8 5 3
0 3 1.8
1 3 1.8
2 1 0.6
7 1 0.6
Total 164 100
Group 4 Breast: Oncotype DX Risk Level Invasive
Answer N Percent
1 132 80.5 9 10 6.1
0 9 5.5
2 7 4.3
8 3 1.8
6 2 1.2
7 1 0.6
Total 164 100
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 101
Group 4 Breast: Response Neoadjuv Therapy Answer N Percent
0 141 86 9 21 12.8
1 1 0.6
8 1 0.6
Total 164 100
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 102
Group 4-Colon and Rectum
Group 4 Colon and Rectum: Primary Site Answer N Percent
C187 156 96.3 C188 2 1.2
C189 2 1.2
C185 1 0.6
C199 1 0.6
Total 162 100
Group 4 Colon and Rectum: Histology Answer N Percent
8140 162 100 Total 162 100
Group 4 Colon and Rectum: Behavior Answer N Percent
3 160 98.8 1 2 1.2
Total 162 100
Group 4 Colon and Rectum: Tumor Size Clinical Answer N Percent
999 154 95.1 000 3 1.9
025 3 1.9
064 1 0.6
998 1 0.6
Total 162 100
Group 4 Colon and Rectum: Tumor Size Pathologic
Answer N Percent
025 156 96.3 250 3 1.9
Answer N Percent
003 1 0.6
028 1 0.6
999 1 0.6
Total 162 100
Group 4 Colon and Rectum: EOD Primary Tumor
Answer N Percent
400 99 61.1 300 54 33.3
200 6 3.7
500 1 0.6
600 1 0.6
999 1 0.6
Total 162 100
Group 4 Colon and Rectum: EOD Regional Nodes
Answer N Percent
000 160 98.8 300 1 0.6
999 1 0.6
Total 162 100
Group 4 Colon and Rectum: Regional Nodes Positive
Answer N Percent
00 160 98.8 98 1 0.6
99 1 0.6
Total 162 100
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 103
Group 4 Colon and Rectum: EOD Mets Answer N Percent
00 160 98.8 10 1 0.6
99 1 0.6
Total 162 100
Group 4 Colon and Rectum: SS2018 Answer N Percent
2 115 71 1 43 26.5
3 3 1.9
9 1 0.6
Total 162 100
Group 4 Colon and Rectum: Grade Clinical Answer N Percent
9 154 95.1 1 8 4.9
Total 162 100
Group 4 Colon and Rectum: Grade Pathological Answer N Percent
1 156 96.3 2 4 2.5
3 1 0.6
9 1 0.6
Total 162 100
Group 4 Colon and Rectum: Grade Post Therapy
Answer N Percent
BLANK 128 79 9 33 20.4
1 1 0.6
Total 162 100
Group 4 Colon and Rectum: CEA PreTx Interpretation
Answer N Percent
9 156 96.3 8 4 2.5
0 2 1.2
Total 162 100
Group 4 Colon and Rectum: CEA PreTx Lab Value
Answer N Percent
XXXX.9 153 94.4 XXXX.8 4 2.5
0.0 3 1.9
1.4 1 0.6
99.9 1 0.6
Total 162 100
Group 4 Colon and Rectum: Circumferential Resection Margin
Answer N Percent
XX.9 79 48.8 XX.1 44 27.2
5.0 18 11.1
0.5 10 6.2
00.5 3 1.9
0.0 2 1.2
05.0 1 0.6
50.0 1 0.6
99.9 1 0.6
XX.0 1 0.6
XX.6 1 0.6
XX.8 1 0.6
Total 162 100
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 104
Group 4 Colon and Rectum: KRAS Answer N Percent
9 157 96.9 8 4 2.5
0 1 0.6
Total 162 100
Group 4 Colon and Rectum: Microsatellite Instability
Answer N Percent
0 72 44.4 1 46 28.4
2 24 14.8
9 19 11.7
8 1 0.6
Total 162 100
Group 4 Colon and Rectum: Perineural Invasion
Answer N Percent
0 153 94.4 9 5 3.1
1 4 2.5
Total 162 100
Group 4 Colon and Rectum: Tumor Deposits Answer N Percent
00 155 95.7 X9 6 3.7
01 1 0.6
Total 162 100
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 105
Group 4-Lung
Group 4 Lung: Primary Site Answer N Percent
C341 159 98.1 C348 2 1.2
C349 1 0.6
Total 162 100
Group 4 Lung: Histology Answer N Percent
8140 145 89.5 8046 14 8.6
8000 1 0.6
8043 1 0.6
8070 1 0.6
Total 162 100
Group 4 Lung: Behavior Answer N Percent
3 162 100 Total 162 100
Group 4 Lung: Tumor Size Clinical Answer N Percent
110 94 58 108 33 20.4
011 11 6.8
079 11 6.8
999 8 4.9
075 2 1.2
080 1 0.6
111 1 0.6
989 1 0.6
Total 162 100
Group 4 Lung: Tumor Size Pathologic Answer N Percent
999 157 96.9 000 1 0.6
012 1 0.6
077 1 0.6
090 1 0.6
099 1 0.6
Total 162 100
Group 4 Lung: EOD Primary Tumor Answer N Percent
650 69 42.6 500 53 32.7
700 20 12.3
300 7 4.3
450 4 2.5
400 3 1.9
100 2 1.2
800 2 1.2
600 1 0.6
999 1 0.6
Total 162 100
Group 4 Lung: EOD Regional Nodes Answer N Percent
600 94 58 400 32 19.8
700 29 17.9
000 4 2.5
300 1 0.6
800 1 0.6
999 1 0.6
Total 162 100
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 106
Group 4 Lung: Regional Nodes Positive Answer N Percent
98 126 77.8 97 14 8.6
99 13 8
00 7 4.3
04 1 0.6
95 1 0.6
Total 162 100
Group 4 Lung: EOD Mets Answer N Percent
00 126 77.8 10 27 16.7
70 3 1.9
20 2 1.2
50 2 1.2
30 1 0.6
99 1 0.6
Total 162 100
Group 4 Lung: SS2018 Answer N Percent
7 77 47.5 4 68 42
3 7 4.3
2 5 3.1
1 4 2.5
9 1 0.6
Total 162 100
Group 4 Lung: Grade Clinical Answer N Percent
9 160 98.8 3 2 1.2
Total 162 100
Group 4 Lung: Grade Pathological Answer N Percent
9 159 98.1 3 2 1.2
1 1 0.6
Total 162 100
Group 4 Lung: Grade Post Therapy Answer N Percent
BLANK 129 79.6 9 32 19.8
3 1 0.6
Total 162 100
Group 4 Lung: Separate Tumor Nodules Answer N Percent
0 67 41.4 1 27 16.7
7 24 14.8
9 15 9.3
3 14 8.6
2 10 6.2
4 3 1.9
8 2 1.2
Total 162 100
Group 4 Lung: Visceral and Parietal Pleural Invasion
Answer N Percent
9 72 44.4 3 64 39.5
1 12 7.4
0 9 5.6
4 4 2.5
6 1 0.6
Total 162 100
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 107
Group 4-Lymphoma (CLL/SLL)
Group 4 Lymphoma (CLL/SLL): Primary Site Answer N Percent
C778 65 40.6 C421 52 32.5
C779 20 12.5
C770 9 5.6
C773 8 5
C420 1 0.6
C440 1 0.6
C494 1 0.6
C771 1 0.6
C772 1 0.6
C788 1 0.6
Total 160 100
Group 4 Lymphoma (CLL/SLL): Histology Answer N Percent
9823 160 100 Total 160 100
Group 4 Lymphoma (CLL/SLL): Behavior Answer N Percent
3 159 99.4 0 1 0.6
Total 160 100
Group 4 Lymphoma (CLL/SLL): Tumor Size Clinical
Answer N Percent
999 148 92.5 988 5 3.1
051 2 1.3
000 1 0.6
005 1 0.6
060 1 0.6
Answer N Percent
888 1 0.6
998 1 0.6
Total 160 100
Group 4 Lymphoma (CLL/SLL): Tumor Size Pathologic
Answer N Percent
999 153 95.6 988 5 3.1
888 1 0.6
998 1 0.6
Total 160 100
Group 4 Lymphoma (CLL/SLL): EOD Primary Tumor
Answer N Percent
600 108 67.5 800 20 12.5
700 9 5.6
999 9 5.6
500 6 3.8
100 3 1.9
300 2 1.3
400 2 1.3
200 1 0.6
Total 160 100
Group 4 Lymphoma (CLL/SLL): EOD Regional Nodes
Answer N Percent
888 160 100 Total 160 100
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 108
Group 4 Lymphoma (CLL/SLL): Regional Nodes Positive
Answer N Percent
99 156 97.5 88 2 1.3
98 2 1.3
Total 160 100
Group 4 Lymphoma (CLL/SLL): EOD Mets Answer N Percent
88 160 100 Total 160 100
Group 4 Lymphoma (CLL/SLL): SS2018 Answer N Percent
7 139 86.9 2 13 8.1
9 5 3.1
1 3 1.9
Total 160 100
Group 4 Lymphoma (CLL/SLL): Grade Clinical Answer N Percent
8 160 100 Total 160 100
Group 4 Lymphoma (CLL/SLL): Grade Pathological
Answer N Percent
8 160 100 Total 160 100
Group 4 Lymphoma (CLL/SLL): Grade Post Therapy
Answer N Percent
BLANK 89 55.6
Answer N Percent
8 71 44.4
Total 160 100
Group 4 Lymphoma (CLL/SLL): Adenopathy Answer N Percent
1 152 95 9 7 4.4
0 1 0.6
Total 160 100
Group 4 Lymphoma (CLL/SLL): Anemia Answer N Percent
0 107 66.9 9 40 25
1 13 8.1
Total 160 100
Group 4 Lymphoma (CLL/SLL): HIV Status Answer N Percent
9 144 90 0 14 8.8
8 2 1.3
Total 160 100
Group 4 Lymphoma (CLL/SLL): Lymphocytosis Answer N Percent
9 118 73.8 1 19 11.9
0 14 8.8
6 8 5
7 1 0.6
Total 160 100
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 109
Group 4 Lymphoma (CLL/SLL): NCCN International Prognostic Index (IPI)
Answer N Percent
X9 152 95 00 2 1.3
01 2 1.3
X1 2 1.3
X8 2 1.3
Total 160 100
Group 4 Lymphoma (CLL/SLL): Organomegaly Answer N Percent
0 122 76.3 9 35 21.9
1 3 1.9
Total 160 100
Group 4 Lymphoma (CLL/SLL): Thrombocytopenia
Answer N Percent
1 67 41.9 0 53 33.1
9 22 13.8
6 18 11.3
Total 160 100
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 110
Group 4-Melanoma Skin
Group 4 Melanoma Skin: Primary Site Answer N Percent
C446 157 96.9 C443 2 1.2
C445 2 1.2
C449 1 0.6
Total 162 100
Group 4 Melanoma Skin: Histology Answer N Percent
8720 162 100 Total 162 100
Group 4 Melanoma Skin: Behavior Answer N Percent
3 160 98.8 0 1 0.6
2 1 0.6
Total 162 100
Group 4 Melanoma Skin: Tumor Size Clinical Answer N Percent
008 79 48.8
999 68 42
002 5 3.1
080 4 2.5
165 3 1.9
001 1 0.6
016 1 0.6
067 1 0.6
Total 162 100
Group 4 Melanoma Skin: Tumor Size Pathological
Answer N Percent
999 109 67.3 008 35 21.6
165 5 3.1
002 4 2.5
016 3 1.9
000 2 1.2
001 2 1.2
017 1 0.6
080 1 0.6
Total 162 100
Group 4 Melanoma Skin: EOD Primary Tumor Answer N Percent
999 62 38.3 400 53 32.7
100 26 16
300 17 10.5
000 3 1.9
200 1 0.6
Total 162 100
Group 4 Melanoma Skin: EOD Regional Nodes Answer N Percent
999 91 56.2 000 68 42
400 2 1.2
100 1 0.6
Total 162 100
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 111
Group 4 Melanoma Skin: Regional Nodes Positive
Answer N Percent
99 99 61.1 00 39 24.1
98 22 13.6
02 1 0.6
97 1 0.6
Total 162 100
Group 4 Melanoma Skin: EOD Mets Answer N Percent
00 159 98.1 90 2 1.2
70 1 0.6
Total 162 100
Group 4 Melanoma Skin: SS2018 Answer N Percent
1 100 61.7 9 56 34.6
0 4 2.5
3 1 0.6
7 1 0.6
Total 162 100
Group 4 Melanoma Skin: Grade Clinical Answer N Percent
9 160 98.8 A 1 0.6
B 1 0.6
Total 162 100
Group 4 Melanoma Skin: Grade Pathological Answer N Percent
9 160 98.8
A 1 0.6
D 1 0.6
Total 162 100
Group 4 Melanoma Skin: Grade Post Therapy Answer N Percent
BLANK 135 83.3
9 27 16.7
Total 162 100
Group 4 Melanoma Skin: Sentinel Nodes Examined
Answer N Percent
02 78 48.1 99 29 17.9
98 22 13.6
00 15 9.3
01 14 8.6
95 4 2.5
Total 162 100
Group 4 Melanoma Skin: Sentinel Nodes Positive
Answer N Percent
99 106 65.4 00 42 25.9
98 9 5.6
97 3 1.9
02 1 0.6
95 1 0.6
Total 162 100
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 112
Group 4 Melanoma Skin: Breslow Thickness Answer N Percent
1.7 101 62.3 1.6 24 14.8
XX.9 9 5.6
01.7 8 4.9
01.6 6 3.7
0.2 4 2.5
16.5 3 1.9
0.0 2 1.2
A1.7 2 1.2
XX.1 2 1.2
AX.0 1 0.6
Total 162 100
Group 4 Melanoma Skin: Ulceration Answer N Percent
0 104 64.2 9 57 35.2
1 1 0.6
Total 162 100
Group 4 Melanoma Skin: LDH (Lactate Dehydrogenase) Pretreatment Lab Value
Answer N Percent
216.0 86 53.1 XXXXX.9 38 23.5
00216.0 11 6.8
0.0 5 3.1
XXXXX.7 4 2.5
21.6 3 1.9
0.2 2 1.2
XXXXX.1 2 1.2
XXXXX.8 2 1.2
0.1 1 0.6
00021.6 1 0.6
Answer N Percent
0216.0 1 0.6
2.1 1 0.6
2016.0 1 0.6
216.9 1 0.6
21600.0 1 0.6
218.0 1 0.6
9.9 1 0.6
Total 162 100
Group 4 Melanoma Skin: LDH (Lactate Dehydrogenase) Pretreatment Level
Answer N Percent
0 108 66.7 9 41 25.3
1 10 6.2
7 3 1.9
Total 162 100
Group 4 Melanoma Skin: LDH Upper Limits of Normal
Answer N Percent
226 69 42.6 XX9 40 24.7
216 30 18.5
228 12 7.4
999 4 2.5
119 2 1.2
001 1 0.6
002 1 0.6
220 1 0.6
236 1 0.6
XX8 1 0.6
Total 162 100
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 113
Group 4 Melanoma Skin: Mitotic Rate Melanoma
Answer N Percent
02 106 65.4 X9 42 25.9
X4 3 1.9
00 2 1.2
99 2 1.2
X2 2 1.2
X8 2 1.2
03 1 0.6
X1 1 0.6
X7 1 0.6
Total 162 100
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 114
Group 4-Ovary
Group 4 Ovary: Primary Site Answer N Percent
C569 156 100 Total 156 100
Group 4 Ovary: Histology Answer N Percent
8310 150 96.2
8120 1 0.6
8130 1 0.6
8140 1 0.6
8345 1 0.6
8441 1 0.6
8806 1 0.6
Total 156 100
Group 4 Ovary: Behavior Answer N Percent
3 155 99.4 1 1 0.6
Total 156 100
Group 4 Ovary: Tumor Size Clinical Answer N Percent
126 70 44.9 120 27 17.3
999 23 14.7
150 13 8.3
062 10 6.4
012 3 1.9
015 2 1.3
125 2 1.3
130 2 1.3
135 2 1.3
Answer N Percent
014 1 0.6
140 1 0.6
Total 156 100
Group 4 Ovary: Tumor Size Pathological Answer N Percent
135 144 92.3 140 3 1.9
999 3 1.9
013 2 1.3
000 1 0.6
014 1 0.6
120 1 0.6
125 1 0.6
Total 156 100
Group 4 Ovary: EOD Primary Tumor Answer N Percent
100 149 95.5 150 2 1.3
200 2 1.3
000 1 0.6
350 1 0.6
999 1 0.6
Total 156 100
Group 4 Ovary: EOD Regional Nodes Answer N Percent
000 155 99.4 999 1 0.6
Total 156 100
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 115
Group 4 Ovary: Regional Nodes Positive Answer N Percent
00 151 96.8 98 3 1.9
47 1 0.6
99 1 0.6
Total 156 100
Group 4 Ovary: EOD Mets Answer N Percent
00 154 98.7 30 1 0.6
99 1 0.6
Total 156 100
Group 4 Ovary: SS2018 Answer N Percent
1 153 98.1 2 1 0.6
7 1 0.6
9 1 0.6
Total 156 100
Group 4 Ovary: Grade Clinical Answer N Percent
9 143 91.7 3 12 7.7
1 1 0.6
Total 156 100
Group 4 Ovary: Grade Pathological Answer N Percent
9 86 55.1 3 68 43.6
1 2 1.3
Total 156 100
Group 4 Ovary: Grade Post Therapy Answer N Percent
BLANK 126 80.8 9 29 18.6
3 1 0.6
Total 156 100
Group 4 Ovary: CA-125 PreTX Lab Value Answer N Percent
1 124 79.5 9 27 17.3
7 3 1.9
0 1 0.6
8 1 0.6
Total 156 100
Group 4 Ovary: FIGO Stage Answer N Percent
02 125 80.1 99 27 17.3
01 4 2.6
Total 156 100
Group 4 Ovary: Residual Tumor Volume Post Cytoreduction
Answer N Percent
00 78 50 97 42 26.9
99 19 12.2
92 10 6.4
30 2 1.3
10 1 0.6
20 1 0.6
90 1 0.6
91 1 0.6
98 1 0.6
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 116
Answer N Percent
Total 156 100
Group 4-Prostate
Group 4 Prostate: Primary Site Answer N Percent
C619 159 100 Total 159 100
Group 4 Prostate: Histology Answer N Percent
8140 140 88.1 8550 14 8.8
8010 5 3.1
Total 159 100
Group 4 Prostate: Behavior Answer N Percent
3 159 100 Total 159 100
Group 4 Prostate: Tumor Size Clinical Answer N Percent
999 146 91.8 004 9 5.7
000 3 1.9
099 1 0.6
Total 159 100
Group 4 Prostate: Tumor Size Pathologic Answer N Percent
999 154 96.9
004 2 1.3
000 1 0.6
006 1 0.6
Answer N Percent
099 1 0.6
Total 159 100
Group 4 Prostate: EOD Primary Tumor Answer N Percent
120 120 75.5 300 12 7.5
150 9 5.7
220 5 3.1
100 4 2.5
999 4 2.5
700 3 1.9
000 1 0.6
110 1 0.6
Total 159 100
Group 4 Prostate: Prostate Path Exten Answer N Percent
900 136 85.5 999 11 6.9
300 10 6.3
000 2 1.3
Total 159 100
Group 4 Prostate: EOD Regional Nodes Answer N Percent
000 141 88.7 999 18 11.3
Total 159 100
Group 4 Prostate: Regional Nodes Positive Answer N Percent
98 126 79.2 00 24 15.1
99 9 5.7
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 117
Answer N Percent
Total 159 100
Group 4 Prostate: EOD Mets Answer N Percent
30 137 86.2 00 8 5
70 8 5
10 5 3.1
99 1 0.6
Total 159 100
Group 4 Prostate: SS2018 Answer N Percent
7 143 89.9 1 13 8.2
9 3 1.9
Total 159 100
Group 4 Prostate: Grade Clinical Answer N Percent
3 147 92.5 2 8 5
9 3 1.9
4 1 0.6
Total 159 100
Group 4 Prostate: Grade Pathological Answer N Percent
9 138 86.8 3 20 12.6
2 1 0.6
Total 159 100
Group 4 Prostate: Grade Post Therapy Answer N Percent
BLANK 132 83 9 23 14.5
3 4 2.5
Total 159 100
Group 4 Prostate: PSA Lab Value Answer N Percent
XXX.1 133 83.6 7.1 8 5
XXX.9 5 3.1
7.0 3 1.9
446.6 2 1.3
447.0 2 1.3
0.7 1 0.6
000.1 1 0.6
014.5 1 0.6
407.6 1 0.6
999.9 1 0.6
XXX.7 1 0.6
Total 159 100
Group 4 Prostate: Gleason Patterns Clinical Answer N Percent
43 152 95.6 34 3 1.9
X9 2 1.3
X7 1 0.6
X8 1 0.6
Total 159 100
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 118
Group 4 Prostate: Gleason Score Clinical Answer N Percent
07 155 97.5 X9 2 1.3
03 1 0.6
X7 1 0.6
Total 159 100
Group 4 Prostate: Gleason Patterns Pathological
Answer N Percent
X7 134 84.3 X9 17 10.7
43 6 3.8
34 1 0.6
X8 1 0.6
Total 159 100
Group 4 Prostate: Gleason Score Pathological Answer N Percent
X7 135 84.9 X9 17 10.7
07 7 4.4
Total 159 100
Group 4 Prostate: Gleason Tertiary Pattern Answer N Percent
X7 136 85.5 X9 21 13.2
40 1 0.6
X8 1 0.6
Total 159 100
Group 4 Prostate: Number of Cores Examined Answer N Percent
15 76 47.8 X6 24 15.1
08 19 11.9
04 13 8.2
02 9 5.7
10 4 2.5
12 3 1.9
X9 3 1.9
13 2 1.3
16 2 1.3
07 1 0.6
09 1 0.6
11 1 0.6
X7 1 0.6
Total 159 100
Group 4 Prostate: Number of Cores Positive Answer N Percent
02 148 93.1 10 2 1.3
X6 2 1.3
X9 2 1.3
01 1 0.6
04 1 0.6
08 1 0.6
12 1 0.6
15 1 0.6
Total 159 100
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 119
Group 4-Soft Tissue Abdomen and Thoracic
Group 4 Soft Tissue: Primary Site Answer N Percent
C494 149 96.1 C151 1 0.6
C152 1 0.6
C269 1 0.6
C475 1 0.6
C493 1 0.6
C495 1 0.6
Total 155 100
Group 4 Soft Tissue: Histology Answer N Percent
8803 124 80 8800 15 9.7
9260 7 4.5
9364 4 2.6
8010 1 0.6
8041 1 0.6
8852 1 0.6
8932 1 0.6
9473 1 0.6
Total 155 100
Group 4 Soft Tissue: Behavior Answer N Percent
3 155 100 Total 155 100
Group 4 Soft Tissue: Tumor Size Clinical Answer N Percent
185 100 64.5 180 21 13.5
126 8 5.2
Answer N Percent
132 6 3.9
130 4 2.6
999 4 2.6
019 2 1.3
080 2 1.3
011 1 0.6
012 1 0.6
013 1 0.6
108 1 0.6
160 1 0.6
186 1 0.6
190 1 0.6
989 1 0.6
Total 155 100
Group 4 Soft Tissue: Tumor Size Pathological Answer N Percent
999 83 53.5 090 36 23.2
100 16 10.3
080 10 6.5
115 2 1.3
185 2 1.3
008 1 0.6
009 1 0.6
013 1 0.6
045 1 0.6
130 1 0.6
989 1 0.6
Total 155 100
Group 4 Soft Tissue: EOD Primary Tumor Answer N Percent
100 37 23.9 200 36 23.2
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 120
Answer N Percent
600 21 13.5
400 13 8.4
550 13 8.4
500 10 6.5
300 7 4.5
700 7 4.5
999 7 4.5
750 3 1.9
650 1 0.6
Total 155 100
Group 4 Soft Tissue: EOD Regional Nodes Answer N Percent
000 82 52.9 800 57 36.8
999 16 10.3
Total 155 100
Group 4 Soft Tissue: Regional Nodes Positive Answer N Percent
98 124 80 00 13 8.4
99 13 8.4
97 5 3.2
Total 155 100
Group 4 Soft Tissue: EOD Mets Answer N Percent
00 80 51.6 70 46 29.7
10 27 17.4
99 2 1.3
Total 155 100
Group 4 Soft Tissue: SS2018 Answer N Percent
7 61 39.4 2 41 26.5
1 25 16.1
4 15 9.7
3 9 5.8
9 4 2.6
Total 155 100
Group 4 Soft Tissue: Grade Clinical Answer N Percent
9 74 47.7 C 62 40
3 15 9.7
D 2 1.3
1 1 0.6
2 1 0.6
Total 155 100
Group 4 Soft Tissue: Grade Pathological Answer N Percent
9 118 76.1 C 23 14.8
3 12 7.7
1 1 0.6
D 1 0.6
Total 155 100
Group 4 Soft Tissue: Grade Post Therapy Answer N Percent
9 97 62.6 BLANK 32 20.6
C 21 13.5
3 5 3.2
Total 155 100
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 121
Group 4 Soft Tissue: Bone Invasion Answer N Percent
0 148 95.5 9 6 3.9
1 1 0.6
Total 155 100
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 122
Group 4-Tongue Anterior
Group 4 Tongue Anterior: Primary Site Answer N Percent
C021 80 51.3 C023 36 23.1
C029 20 12.8
C022 8 5.1
C020 6 3.8
C028 6 3.8
Total 156 100
Group 4 Tongue Anterior: Histology Answer N Percent
8070 153 98.1 8071 2 1.3
9700 1 0.6
Total 156 100
Group 4 Tongue Anterior: Behavior Answer N Percent
3 154 98.7 0 1 0.6
2 1 0.6
Total 156 100
Group 4 Tongue Anterior: Tumor Size Clinical Answer N Percent
030 79 50.6 035 45 28.8
015 17 10.9
020 7 4.5
013 4 2.6
002 1 0.6
003 1 0.6
031 1 0.6
Answer N Percent
999 1 0.6
Total 156 100
Group 4 Tongue Anterior: Tumor Size Pathologic
Answer N Percent
041 144 92.3 040 4 2.6
020 3 1.9
999 2 1.3
002 1 0.6
035 1 0.6
410 1 0.6
Total 156 100
Group 4 Tongue Anterior: EOD Primary Tumor Answer N Percent
500 81 51.9 200 59 37.8
300 5 3.2
100 3 1.9
150 2 1.3
400 2 1.3
999 2 1.3
600 1 0.6
700 1 0.6
Total 156 100
Group 4 Tongue Anterior: EOD Regional Nodes Answer N Percent
600 121 77.6 250 16 10.3
500 6 3.8
700 4 2.6
150 3 1.9
100 2 1.3
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 123
Answer N Percent
000 1 0.6
200 1 0.6
300 1 0.6
999 1 0.6
Total 156 100
Group 4 Tongue Anterior: Regional Nodes Positive
Answer N Percent
10 136 87.2 97 11 7.1
11 3 1.9
00 2 1.3
05 1 0.6
07 1 0.6
17 1 0.6
99 1 0.6
Total 156 100
Group 4 Tongue Anterior: EOD Mets Answer N Percent
00 148 94.9 99 5 3.2
10 2 1.3
70 1 0.6
Total 156 100
Group 4 Tongue Anterior: EOD Mets Answer N Percent
00 148 94.9 99 5 3.2
10 2 1.3
70 1 0.6
Total 156 100
Group 4 Tongue Anterior: SS2018 Answer N Percent
4 77 49.4 3 70 44.9
7 4 2.6
1 3 1.9
2 1 0.6
9 1 0.6
Total 156 100
Group 4 Tongue Anterior: Grade Clinical Answer N Percent
2 95 60.9 9 54 34.6
3 5 3.2
1 2 1.3
Total 156 100
Group 4 Tongue Anterior: Grade Pathological Answer N Percent
3 146 93.6 2 5 3.2
9 5 3.2
Total 156 100
Group 4 Tongue Anterior: Grade Post Therapy Answer N Percent
BLANK 125 80.1 9 27 17.3
3 4 2.6
Total 156 100
Group 4 Tongue Anterior: Extranodal Exten H&N Clin
Answer N Percent
0 58 37.2 1 51 32.7
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 124
Answer N Percent
9 27 17.3
2 18 11.5
7 1 0.6
8 1 0.6
Total 156 100
Group 4 Tongue Anterior: Extranodal Exten H&N Path
Answer N Percent
3.0 65 41.7 X.3 29 18.6
X.1 16 10.3
X.4 10 6.4
0.3 8 5.1
2.1 6 3.8
X.9 5 3.2
2.0 4 2.6
3.1 4 2.6
0.0 2 1.3
3.3 2 1.3
X.2 2 1.3
0.1 1 0.6
0.2 1 0.6
1.0 1 0.6
Total 156 100
Group 4 Tongue Anterior: LN Size Answer N Percent
31.0 34 21.8 XX.9 29 18.6
3.1 24 15.4
10.0 10 6.4
13.0 10 6.4
1.0 9 5.8
XX.5 9 5.8
Answer N Percent
03.1 6 3.8
30.1 4 2.6
0.3 3 1.9
XX.1 3 1.9
1.3 2 1.3
3.0 2 1.3
XX.4 2 1.3
0.0 1 0.6
01.0 1 0.6
01.3 1 0.6
15.0 1 0.6
2.1 1 0.6
2.2 1 0.6
30.0 1 0.6
XX.3 1 0.6
XX.7 1 0.6
Total 156 100
Group 4 Tongue Anterior: SEER SSF: Human Papilloma Virus (HPV) Status
Answer N Percent
9 148 94.9 0 7 4.5
1 1 0.6
Total 156 100
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 125
Group 5-Brain
Group 5 Brain: Primary Site Answer N Percent
C711 162 95.9 C714 2 1.2
C717 2 1.2
C710 1 0.6
C712 1 0.6
C719 1 0.6
Total 169 100
Group 5 Brain: Histology Answer N Percent
9451 152 89.9 9450 8 4.7
9382 3 1.8
8000 2 1.2
9440 2 1.2
9100 1 0.6
9401 1 0.6
Total 169 100
Group 5 Brain: Behavior Answer N Percent
3 168 99.4 0 1 0.6
Total 169 100
Group 5 Brain: Tumor Size Clinical Answer N Percent
045 96 56.8 047 57 33.7
017 7 4.1
999 3 1.8
005 1 0.6
Answer N Percent
042 1 0.6
048 1 0.6
227 1 0.6
450 1 0.6
470 1 0.6
Total 169 100
Group 5 Brain: Tumor Size Pathological Answer N Percent
999 153 90.5 047 8 4.7
010 6 3.6
080 2 1.2
Total 169 100
Group 5 Brain: EOD Primary Tumor Answer N Percent
100 149 88.2 999 13 7.7
500 3 1.8
800 2 1.2
050 1 0.6
700 1 0.6
Total 169 100
Group 5 Brain: EOD Regional Nodes Answer N Percent
888 169 100 Total 169 100
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 126
Group 5 Brain: Regional Nodes Positive Answer N Percent
99 152 89.9 98 9 5.3
00 5 3
88 3 1.8
Total 169 100
Group 5 Brain: EOD Mets Answer N Percent
00 163 96.4 99 6 3.6
Total 169 100
Group 5 Brain: SS2018 Answer N Percent
1 158 93.5
9 5 3
7 3 1.8
2 2 1.2
8 1 0.6
Total 169 100
Group 5 Brain: Grade Clinical Answer N Percent
9 107 63.3 H 43 25.4
3 15 8.9
4 3 1.8
2 1 0.6
Total 169 100
Group 5 Brain: Grade Pathological Answer N Percent
3 142 84 9 13 7.7
4 5 3
D 5 3
2 3 1.8
H 1 0.6
Total 169 100
Group 5 Brain: Grade Post Therapy Answer N Percent
BLANK 139 82.2
9 27 16
3 2 1.2
D 1 0.6
Total 169 100
Group 5 Brain: Brain Molecular Markers Answer N Percent
07 124 73.4 06 26 15.4
88 6 3.6
99 6 3.6
03 2 1.2
05 2 1.2
85 2 1.2
87 1 0.6
Total 169 100
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 127
Group 5 Brain: Brain Molecular Markers Answer N Percent
07 124 73.4 06 26 15.4
88 6 3.6
99 6 3.6
03 2 1.2
05 2 1.2
85 2 1.2
87 1 0.6
Total 169 100
Group 5 Brain: Chromosome 1p Status Answer N Percent
1 112 66.3 9 25 14.8
0 22 13
8 5 3
6 4 2.4
7 1 0.6
Total 169 100
Group 5 Brain: Chromosome 19q Status Answer N Percent
1 110 65.1 9 25 14.8
0 23 13.6
8 6 3.6
7 3 1.8
6 2 1.2
Total 169 100
Group 5 Brain: MGMT Answer N Percent
9 150 88.8 8 10 5.9
0 3 1.8
1 3 1.8
2 1 0.6
3 1 0.6
7 1 0.6
Total 169 100
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 128
Group 5-Breast
Group 5 Breast: Primary Site Answer N Percent
C504 165 98.2 C509 2 1.2
C508 1 0.6
Total 168 100
Group 5 Breast: Histology Answer N Percent
8520 148 88.1 8022 9 5.4
8500 3 1.8
8027 1 0.6
8250 1 0.6
8255 1 0.6
8519 1 0.6
8522 1 0.6
8524 1 0.6
8525 1 0.6
8530 1 0.6
Total 168 100
Group 5 Breast: Behavior Answer N Percent
3 165 98.2 2 2 1.2
0 1 0.6
Total 168 100
Group 5 Breast: Tumor Size Clinical Answer N Percent
028 94 56 080 29 17.3
050 24 14.3
280 7 4.2
Answer N Percent
017 6 3.6
005 2 1.2
030 2 1.2
025 1 0.6
029 1 0.6
037 1 0.6
800 1 0.6
Total 168 100
Group 5 Breast: Tumor Size Pathologic Answer N Percent
999 153 91.1 028 7 4.2
017 4 2.4
000 1 0.6
014 1 0.6
080 1 0.6
998 1 0.6
Total 168 100
Group 5 Breast: EOD Primary Tumor Answer N Percent
100 145 86.3 200 8 4.8
999 8 4.8
300 4 2.4
000 1 0.6
050 1 0.6
700 1 0.6
Total 168 100
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 129
Group 5 Breast: EOD Regional Nodes Answer N Percent
150 89 53 200 43 25.6
800 12 7.1
100 6 3.6
999 5 3
000 4 2.4
250 3 1.8
050 2 1.2
600 2 1.2
030 1 0.6
350 1 0.6
Total 168 100
Group 5 Breast: Regional Nodes Positive Answer N Percent
95 97 57.7 01 50 29.8
98 10 6
00 3 1.8
97 3 1.8
99 3 1.8
03 1 0.6
07 1 0.6
Total 168 100
Group 5 Breast: EOD Mets Answer N Percent
70 155 92.3 00 8 4.8
10 3 1.8
05 2 1.2
Total 168 100
Group 5 Breast: SS2018 Answer N Percent
7 148 88.1 1 9 5.4
3 7 4.2
0 1 0.6
2 1 0.6
4 1 0.6
9 1 0.6
Total 168 100
Group 5 Breast: Grade Clinical Answer N Percent
2 156 92.9 3 6 3.6
9 3 1.8
1 1 0.6
B 1 0.6
M 1 0.6
Total 168 100
Group 5 Breast: Grade Pathological Answer N Percent
9 134 79.8 2 30 17.9
3 3 1.8
B 1 0.6
Total 168 100
Group 5 Breast: Grade Post Therapy Answer N Percent
BLANK 138 82.1 9 27 16.1
2 2 1.2
3 1 0.6
Total 168 100
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 130
Group 5 Breast: Sentinel Lymph Nodes Examined
Answer N Percent
00 86 51.2 98 40 23.8
95 18 10.7
01 14 8.3
99 8 4.8
03 1 0.6
09 1 0.6
Total 168 100
Group 5 Breast: Sentinel Lymph Nodes Positive Answer N Percent
00 63 37.5 98 57 33.9
95 17 10.1
01 16 9.5
99 14 8.3
09 1 0.6
Total 168 100
Group 5 Breast: ER Summary Answer N Percent
1 165 98.2 0 3 1.8
Total 168 100
Group 5 Breast: ER Percent Positive Answer N Percent
095 116 69 R99 29 17.3
XX9 14 8.3
000 2 1.2
020 1 0.6
035 1 0.6
Answer N Percent
085 1 0.6
099 1 0.6
100 1 0.6
R40 1 0.6
R90 1 0.6
Total 168 100
Group 5 Breast: ER Allred Score Answer N Percent
08 153 91.1 X9 6 3.6
07 4 2.4
01 2 1.2
00 1 0.6
05 1 0.6
X8 1 0.6
Total 168 100
Group 5 Breast: PR Summary Answer N Percent
1 161 95.8 0 3 1.8
9 3 1.8
7 1 0.6
Total 168 100
Group 5 Breast: PR Percent Positive Answer N Percent
035 118 70.2 R40 27 16.1
XX9 13 7.7
R99 3 1.8
095 2 1.2
015 1 0.6
020 1 0.6
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 131
Answer N Percent
032 1 0.6
R10 1 0.6
R30 1 0.6
Total 168 100
Group 5 Breast: PR Allred Score Answer N Percent
07 147 87.5 08 11 6.5
X9 8 4.8
00 1 0.6
01 1 0.6
Total 168 100
Group 5 Breast: HER2 IHC Summary Answer N Percent
0 143 85.1 9 9 5.4
4 8 4.8
1 5 3
2 2 1.2
7 1 0.6
Total 168 100
Group 5 Breast: HER2 ISH Summary Answer N Percent
9 134 79.8 0 25 14.9
8 6 3.6
2 2 1.2
3 1 0.6
Total 168 100
Group 5 Breast: HER2 Overall Summary Answer N Percent
0 158 94 9 6 3.6
1 4 2.4
Total 168 100
Group 5 Breast: HER2 ISH SP Copy No Answer N Percent
XX.9 147 87.5 XX.8 9 5.4
0.0 7 4.2
99.9 3 1.8
00.8 1 0.6
XX.7 1 0.6
Total 168 100
Group 5 Breast: HER2 ISH DP Copy No Answer N Percent
XX.9 145 86.3 XX.8 10 6
0.0 8 4.8
99.9 3 1.8
00.8 1 0.6
XX.7 1 0.6
Total 168 100
Group 5 Breast: HER2 ISH DP Ratio Answer N Percent
XX.9 147 87.5 XX.8 9 5.4
0.0 7 4.2
99.9 3 1.8
00.8 1 0.6
XX.7 1 0.6
Total 168 100
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 132
Group 5 Breast: Ki-67 (MIB-1) Answer N Percent
15.0 145 86.3 015.0 12 7.1
XXX.9 4 2.4
14.0 3 1.8
0.0 1 0.6
001.5 1 0.6
35.0 1 0.6
XXX.8 1 0.6
Total 168 100
Group 5 Breast: Lymph Nodes Positive Axillary Level I-III
Answer N Percent
X6 91 54.2 01 51 30.4
X5 6 3.6
X9 6 3.6
95 5 3
00 3 1.8
98 2 1.2
X8 2 1.2
03 1 0.6
99 1 0.6
Total 168 100
Group 5 Breast: Multigene Signature Method Answer N Percent
9 155 92.3 8 10 6
2 1 0.6
5 1 0.6
7 1 0.6
Total 168 100
Group 5 Breast: Multigene Signature Result Answer N Percent
X9 148 88.1 X8 10 6
99 4 2.4
00 2 1.2
08 1 0.6
09 1 0.6
X2 1 0.6
X7 1 0.6
Total 168 100
Group 5 Breast: Oncotype DX Recur Score-DCIS Answer N Percent
XX6 106 63.1 XX9 51 30.4
XX8 8 4.8
000 1 0.6
008 1 0.6
XX7 1 0.6
Total 168 100
Group 5 Breast: Oncotype DX Recur Score Answer N Percent
XX9 161 95.8 000 3 1.8
008 1 0.6
009 1 0.6
XX6 1 0.6
XX7 1 0.6
Total 168 100
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 133
Group 5 Breast: Oncotype DX Risk Level-DCIS Answer N Percent
6 98 58.3 9 60 35.7
8 7 4.2
0 1 0.6
2 1 0.6
7 1 0.6
Total 168 100
Group 5 Breast: Oncotype DX Risk Level Invasive
Answer N Percent
9 156 92.9 8 8 4.8
0 2 1.2
6 1 0.6
7 1 0.6
Total 168 100
Group 5 Breast: Response Neoadjuv Therapy Answer N Percent
0 131 78 9 29 17.3
8 6 3.6
1 1 0.6
3 1 0.6
Total 168 100
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 134
Group 5-Colon and Rectum
Group 5 Colon and Rectum: Primary Site Answer N Percent
C186 164 97.6 C189 2 1.2
C180 1 0.6
C199 1 0.6
Total 168 100
Group 5 Colon and Rectum: Histology Answer N Percent
8140 165 98.2 8263 2 1.2
8000 1 0.6
Total 168 100
Group 5 Colon and Rectum: Behavior Answer N Percent
3 165 98.2 2 3 1.8
Total 168 100
Group 5 Colon and Rectum: Tumor Size Clinical Answer N Percent
038 144 85.7 999 10 6
045 8 4.8
027 2 1.2
028 1 0.6
037 1 0.6
380 1 0.6
450 1 0.6
Total 168 100
Group 5 Colon and Rectum: Tumor Size Pathological
Answer N Percent
045 164 97.6 450 2 1.2
050 1 0.6
999 1 0.6
Total 168 100
Group 5 Colon and Rectum: EOD Primary Tumor
Answer N Percent
500 127 75.6 400 13 7.7
300 12 7.1
600 6 3.6
700 3 1.8
000 2 1.2
999 2 1.2
050 1 0.6
100 1 0.6
800 1 0.6
Total 168 100
Group 5 Colon and Rectum: EOD Regional Nodes
Answer N Percent
300 128 76.2 800 33 19.6
200 6 3.6
999 1 0.6
Total 168 100
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 135
Group 5 Colon and Rectum: Regional Nodes Positive
Answer N Percent
03 167 99.4 01 1 0.6
Total 168 100
Group 5 Colon and Rectum: EOD Mets Answer N Percent
50 74 44 20 45 26.8
70 27 16.1
00 17 10.1
10 3 1.8
40 2 1.2
Total 168 100
Group 5 Colon and Rectum: SS2018 Answer N Percent
7 129 76.8 4 17 10.1
2 12 7.1
3 5 3
1 3 1.8
0 1 0.6
9 1 0.6
Total 168 100
Group 5 Colon and Rectum: Grade Clinical Answer N Percent
2 153 91.1 9 15 8.9
Total 168 100
Group 5 Colon and Rectum: Grade Pathological Answer N Percent
2 167 99.4 9 1 0.6
Total 168 100
Group 5 Colon and Rectum: Grade Post Therapy
Answer N Percent
BLANK 138 82.1 9 28 16.7
2 2 1.2
Total 168 100
Group 5 Colon and Rectum: CEA PreTX Interpretation
Answer N Percent
9 128 76.2 1 28 16.7
0 8 4.8
8 4 2.4
Total 168 100
Group 5 Colon and Rectum: CEA PreTX Lab Value
Answer N Percent
XXXX.9 123 73.2 2.8 31 18.5
XXXX.8 5 3
0002.8 2 1.2
0.0 1 0.6
0.3 1 0.6
02.8 1 0.6
2.3 1 0.6
3.0 1 0.6
9.9 1 0.6
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 136
Answer N Percent
9999.9 1 0.6
Total 168 100
Group 5 Colon and Rectum: Circumferential Resection Margin
Answer N Percent
XX.1 86 51.2 XX.9 37 22
20.0 21 12.5
0.0 5 3
2.0 5 3
XX.0 3 1.8
00.1 2 1.2
XX.8 2 1.2
0.2 1 0.6
02.0 1 0.6
10.0 1 0.6
13.6 1 0.6
99.9 1 0.6
XX.4 1 0.6
XX.6 1 0.6
Total 168 100
Group 5 Colon and Rectum: KRAS Answer N Percent
0 129 76.8 7 21 12.5
9 13 7.7
8 2 1.2
1 1 0.6
3 1 0.6
4 1 0.6
Total 168 100
Group 5 Colon and Rectum: Microsatellite Instability
Answer N Percent
0 163 97 1 3 1.8
8 1 0.6
9 1 0.6
Total 168 100
Group 5 Colon and Rectum: Perineural Invasion
Answer N Percent
0 162 96.4 1 5 3
8 1 0.6
Total 168 100
Group 5 Colon and Rectum: Tumor Deposits Answer N Percent
00 158 94 X9 5 3
01 2 1.2
X8 2 1.2
99 1 0.6
Total 168 100
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 137
Group 5-Lung
Group 5 Lung: Primary Site Answer N Percent
C341 165 98.8 C340 1 0.6
C349 1 0.6
Total 167 100
Group 5 Lung: Histology Answer N Percent
8551 77 46.1 8140 53 31.7
8550 22 13.2
8255 14 8.4
8230 1 0.6
Total 167 100
Group 5 Lung: Behavior Answer N Percent
3 166 99.4 0 1 0.6
Total 167 100
Group 5 Lung: Tumor Size Clinical Answer N Percent
028 156 93.4 025 4 2.4
999 4 2.4
280 2 1.2
030 1 0.6
Total 167 100
Group 5 Lung: Tumor Size Pathologic Answer N Percent
025 159 95.2 999 4 2.4
250 2 1.2
021 1 0.6
028 1 0.6
Total 167 100
Group 5 Lung: EOD Primary Tumor Answer N Percent
450 107 64.1
650 25 15
300 15 9
100 10 6
400 5 3
000 2 1.2
999 2 1.2
200 1 0.6
Total 167 100
Group 5 Lung: EOD Regional Nodes Answer N Percent
400 107 64.1 300 39 23.4
700 14 8.4
800 5 3
000 1 0.6
999 1 0.6
Total 167 100
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 138
Group 5 Lung: Regional Nodes Positive Answer N Percent
04 141 84.4 03 16 9.6
06 4 2.4
05 3 1.8
18 1 0.6
19 1 0.6
97 1 0.6
Total 167 100
Group 5 Lung: EOD Mets Answer N Percent
00 158 94.6 10 3 1.8
50 3 1.8
70 2 1.2
20 1 0.6
Total 167 100
Group 5 Lung: SS2018 Answer N Percent
4 108 64.7 3 41 24.6
2 7 4.2
7 5 3
0 2 1.2
1 2 1.2
9 2 1.2
Total 167 100
Group 5 Lung: Grade Clinical Answer N Percent
9 164 98.2 2 2 1.2
3 1 0.6
Total 167 100
Group 5 Lung: Grade Pathological Answer N Percent
9 163 97.6 2 2 1.2
3 2 1.2
Total 167 100
Group 5 Lung: Grade Post Therapy Answer N Percent
BLANK 143 85.6 9 22 13.2
1 1 0.6
2 1 0.6
Total 167 100
Group 5 Lung: Separate Tumor Nodules Answer N Percent
0 162 97 9 2 1.2
1 1 0.6
7 1 0.6
8 1 0.6
Total 167 100
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 139
Group 5 Lung: Visceral and Parietal Pleural Invasion
Answer N Percent
4 106 63.5 1 36 21.6
0 9 5.4
2 9 5.4
9 4 2.4
6 3 1.8
Total 167 100
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 140
Group 5-Lymphoma (CLL/SLL)
Group 5 Lymphoma (CLL/SLL): Primary Site Answer N Percent
C770 124 75.6 C421 29 17.7
C778 4 2.4
C779 3 1.8
C739 2 1.2
C760 1 0.6
C773 1 0.6
Total 164 100
Group 5 Lymphoma (CLL/SLL): Histology Answer N Percent
9823 164 100 Total 164 100
Group 5 Lymphoma (CLL/SLL): Behavior Answer N Percent
3 164 100
Total 164 100
Group 5 Lymphoma (CLL/SLL): Tumor Size Clinical
Answer N Percent
999 152 92.7 026 7 4.3
988 2 1.2
019 1 0.6
025 1 0.6
888 1 0.6
Total 164 100
Group 5 Lymphoma (CLL/SLL): Tumor Size Pathologic
Answer N Percent
999 158 96.3 025 2 1.2
988 2 1.2
019 1 0.6
888 1 0.6
Total 164 100
Group 5 Lymphoma (CLL/SLL): EOD Primary Tumor
Answer N Percent
100 136 82.9
800 13 7.9
999 6 3.7
400 3 1.8
700 3 1.8
300 2 1.2
200 1 0.6
Total 164 100
Group 5 Lymphoma (CLL/SLL): EOD Regional Nodes
Answer N Percent
888 164 100
Total 164 100
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 141
Group 5 Lymphoma (CLL/SLL): Regional Nodes Positive
Answer N Percent
99 156 95.1 88 4 2.4
00 1 0.6
02 1 0.6
04 1 0.6
98 1 0.6
Total 164 100
Group 5 Lymphoma (CLL/SLL): EOD Mets Answer N Percent
88 164 100
Total 164 100
Group 5 Lymphoma (CLL/SLL): SS2018 Answer N Percent
1 130 79.3 7 25 15.2
9 5 3
2 4 2.4
Total 164 100
Group 5 Lymphoma (CLL/SLL): Grade Clinical Answer N Percent
8 164 100
Total 164 100
Group 5 Lymphoma (CLL/SLL): Grade Pathological
Answer N Percent
8 164 100
Total 164 100
Group 5 Lymphoma (CLL/SLL): Grade Post Therapy
Answer N Percent
BLANK 101 61.6 8 63 38.4
Total 164 100
Group 5 Lymphoma (CLL/SLL): Adenopathy Answer N Percent
1 148 90.2 0 10 6.1
9 6 3.7
Total 164 100
Group 5 Lymphoma (CLL/SLL): Anemia Answer N Percent
0 109 66.5 9 51 31.1
1 4 2.4
Total 164 100
Group 5 Lymphoma (CLL/SLL): B Symptoms Answer N Percent
0 145 88.4 9 12 7.3
1 5 3
8 2 1.2
Total 164 100
Group 5 Lymphoma (CLL/SLL): HIV Status Answer N Percent
9 81 49.4 0 79 48.2
8 3 1.8
1 1 0.6
Total 164 100
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 142
Group 5 Lymphoma (CLL/SLL): Lymphocytosis Answer N Percent
0 84 51.2 9 72 43.9
1 6 3.7
6 1 0.6
7 1 0.6
Total 164 100
Group 5 Lymphoma (CLL/SLL): NCCN International Prognostic Index (IPI)
Answer N Percent
X9 153 93.3 X8 5 3
00 4 2.4
01 1 0.6
X1 1 0.6
Total 164 100
Group 5 Lymphoma (CLL/SLL): Organomegaly Answer N Percent
0 126 76.8 9 38 23.2
Total 164 100
Group 5 Lymphoma (CLL/SLL): Thrombocytopenia
Answer N Percent
0 101 61.6 9 57 34.8
1 6 3.7
Total 164 100
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 143
Group 5-Melanoma Skin
Group 5 Melanoma Skin: Primary Site Answer N Percent
C447 164 98.8 C445 1 0.6
C449 1 0.6
Total 166 100
Group 5 Melanoma Skin: Histology Answer N Percent
8720 101 60.8 8743 63 38
8740 2 1.2
Total 166 100
Group 5 Melanoma Skin: Behavior Answer N Percent
3 166 100
Total 166 100
Group 5 Melanoma Skin: Tumor Size Clinical Answer N Percent
999 143 86.1 010 11 6.6
055 4 2.4
006 3 1.8
001 2 1.2
005 1 0.6
008 1 0.6
009 1 0.6
Total 166 100
Group 5 Melanoma Skin: Tumor Size Pathologic
Answer N Percent
999 147 88.6 009 7 4.2
010 3 1.8
005 2 1.2
000 1 0.6
001 1 0.6
006 1 0.6
008 1 0.6
055 1 0.6
090 1 0.6
095 1 0.6
Total 166 100
Group 5 Melanoma Skin: EOD Primary Tumor Answer N Percent
300 149 89.8 100 6 3.6
000 4 2.4
400 3 1.8
999 2 1.2
200 1 0.6
500 1 0.6
Total 166 100
Group 5 Melanoma Skin: EOD Regional Nodes Answer N Percent
000 160 96.4 999 3 1.8
100 1 0.6
300 1 0.6
500 1 0.6
Total 166 100
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 144
Group 5 Melanoma Skin: Regional Nodes Positive
Answer N Percent
00 150 90.4 98 13 7.8
99 3 1.8
Total 166 100
Group 5 Melanoma Skin: EOD Mets Answer N Percent
00 165 99.4 10 1 0.6
Total 166 100
Group 5 Melanoma Skin: SS2018 Answer N Percent
1 157 94.6 0 4 2.4
3 2 1.2
9 2 1.2
2 1 0.6
Total 166 100
Group 5 Melanoma Skin: Grade Clinical Answer N Percent
9 162 97.6 A 2 1.2
B 1 0.6
D 1 0.6
Total 166 100
Group 5 Melanoma Skin: Grade Pathological Answer N Percent
9 162 97.6 B 2 1.2
A 1 0.6
Answer N Percent
D 1 0.6
Total 166 100
Group 5 Melanoma Skin: Grade Post Therapy Answer N Percent
BLANK 140 84.3 9 25 15.1
A 1 0.6
Total 166 100
Group 5 Melanoma Skin: Sentinel Lymph Nodes Examined
Answer N Percent
01 154 92.8 00 7 4.2
98 4 2.4
03 1 0.6
Total 166 100
Group 5 Melanoma Skin: Sentinel Lymph Nodes Positive
Answer N Percent
00 159 95.8 01 4 2.4
98 3 1.8
Total 166 100
Group 5 Melanoma Skin: Breslow Thickness Answer N Percent
0.9 118 71.1 0.6 21 12.7
00.9 6 3.6
A0.6 6 3.6
XX.9 3 1.8
0.5 2 1.2
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 145
Answer N Percent
1.0 2 1.2
A0.9 2 1.2
0.4 1 0.6
5.5 1 0.6
55.0 1 0.6
6.0 1 0.6
99.9 1 0.6
XX.1 1 0.6
Total 166 100
Group 5 Melanoma Skin: Ulceration Answer N Percent
0 160 96.4 1 3 1.8
9 3 1.8
Total 166 100
Group 5 Melanoma Skin: LDH (Lactate Dehydrogenase) Pretreatment Lab Value
Answer N Percent
XXXXX.9 157 94.6 0.0 3 1.8
0.9 3 1.8
99999.9 1 0.6
XXXXX.7 1 0.6
XXXXX.8 1 0.6
Total 166 100
Group 5 Melanoma Skin: LDH (Lactate Dehydrogenase) Pretreatment Level
Answer N Percent
9 163 98.2 0 2 1.2
7 1 0.6
Total 166 100
Group 5 Melanoma Skin: LDH Upper Limits of Normal
Answer N Percent
XX9 154 92.8 999 9 5.4
009 1 0.6
998 1 0.6
XX8 1 0.6
Total 166 100
Group 5 Melanoma Skin: Mitotic Rate Melanoma
Answer N Percent
01 144 86.7 00 7 4.2
X3 5 3
99 2 1.2
X1 2 1.2
X9 2 1.2
02 1 0.6
09 1 0.6
X7 1 0.6
X8 1 0.6
Total 166 100
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 146
Group 5-Ovary
Group 5 Ovary: Primary Site Answer N Percent
C569 164 100 Total 164 100
Group 5 Ovary: Histology Answer N Percent
8441 81 49.4
8461 50 30.5
8460 23 14
8323 9 5.5
8050 1 0.6
Total 164 100
Group 5 Ovary: Behavior Answer N Percent
3 163 99.4 1 1 0.6
Total 164 100
Group 5 Ovary: Tumor Size Clinical Answer N Percent
999 147 89.6 027 7 4.3
000 3 1.8
003 2 1.2
030 2 1.2
040 2 1.2
010 1 0.6
Total 164 100
Group 5 Ovary: Tumor Size Pathologic Answer N Percent
030 143 87.2 999 10 6.1
003 8 4.9
015 1 0.6
033 1 0.6
035 1 0.6
Total 164 100
Group 5 Ovary: EOD Primary Tumor Answer N Percent
650 124 75.6 750 20 12.2
700 7 4.3
300 4 2.4
000 2 1.2
450 2 1.2
600 2 1.2
400 1 0.6
800 1 0.6
999 1 0.6
Total 164 100
Group 5 Ovary: EOD Regional Nodes Answer N Percent
000 85 51.8 999 78 47.6
500 1 0.6
Total 164 100
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 147
Group 5 Ovary: Regional Nodes Positive Answer N Percent
98 132 80.5 00 17 10.4
99 14 8.5
97 1 0.6
Total 164 100
Group 5 Ovary: EOD Mets Answer N Percent
00 100 61 50 48 29.3
70 10 6.1
10 3 1.8
99 2 1.2
30 1 0.6
Total 164 100
Group 5 Ovary: SS2018 Answer N Percent
7 149 90.9 2 7 4.3
4 3 1.8
1 2 1.2
9 2 1.2
0 1 0.6
Total 164 100
Group 5 Ovary: Grade Clinical Answer N Percent
9 88 53.7 H 37 22.6
L 35 21.3
3 3 1.8
1 1 0.6
Total 164 100
Group 5 Ovary: Grade Pathological Answer N Percent
H 151 92.1 9 7 4.3
3 4 2.4
L 2 1.2
Total 164 100
Group 5 Ovary: Grade Post Therapy Answer N Percent
BLANK 141 86 9 18 11
H 4 2.4
3 1 0.6
Total 164 100
Group 5 Ovary: CA-125 PreTX Lab Value Answer N Percent
1 151 92.1 9 8 4.9
0 2 1.2
8 2 1.2
7 1 0.6
Total 164 100
Group 5 Ovary: FIGO Stage Answer N Percent
36 141 86 99 8 4.9
24 3 1.8
30 3 1.8
32 2 1.2
40 2 1.2
42 2 1.2
01 1 0.6
02 1 0.6
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 148
Answer N Percent
10 1 0.6
Total 164 100
Group 5 Ovary: Residual Tumor Volume Post Cytoreduction
Answer N Percent
00 111 67.7 99 19 11.6
97 16 9.8
92 11 6.7
90 3 1.8
30 2 1.2
93 2 1.2
Total 164 100
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 149
Group 5-Prostate
Group 5 Prostate: Primary Site Answer N Percent
C619 166 100 Total 166 100
Group 5 Prostate: Histology Answer N Percent
8140 153 92.2 8550 9 5.4
8500 2 1.2
8410 1 0.6
8551 1 0.6
Total 166 100
Group 5 Prostate: Behavior Answer N Percent
3 165 99.4 0 1 0.6
Total 166 100
Group 5 Prostate: Tumor Size Clinical Answer N Percent
999 156 94 000 8 4.8
099 1 0.6
127 1 0.6
Total 166 100
Group 5 Prostate: Tumor Size Pathological Answer N Percent
999 162 97.6 000 2 1.2
042 1 0.6
127 1 0.6
Total 166 100
Group 5 Prostate: EOD Primary Tumor Answer N Percent
120 84 50.6 350 19 11.4
220 18 10.8
150 17 10.2
300 7 4.2
200 4 2.4
100 3 1.8
500 3 1.8
600 3 1.8
999 3 1.8
110 2 1.2
210 1 0.6
250 1 0.6
400 1 0.6
Total 166 100
Group 5 Prostate: Prostate Path Exten Answer N Percent
900 146 88 999 11 6.6
300 6 3.6
000 1 0.6
250 1 0.6
350 1 0.6
Total 166 100
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 150
Group 5 Prostate: EOD Regional Nodes Answer N Percent
000 115 69.3 999 23 13.9
300 22 13.3
800 6 3.6
Total 166 100
Group 5 Prostate: Regional Nodes Positive Answer N Percent
98 134 80.7 00 21 12.7
99 6 3.6
01 2 1.2
97 2 1.2
02 1 0.6
Total 166 100
Group 5 Prostate: EOD Mets Answer N Percent
00 107 64.5 10 59 35.5
Total 166 100
Group 5 Prostate: SS2018 Answer N Percent
1 71 42.8 7 57 34.3
3 19 11.4
2 10 6
9 5 3
4 3 1.8
0 1 0.6
Total 166 100
Group 5 Prostate: Grade Clinical Answer N Percent
5 152 91.6 3 6 3.6
9 5 3
4 3 1.8
Total 166 100
Group 5 Prostate: Grade Pathological Answer N Percent
9 148 89.2 5 16 9.6
4 2 1.2
Total 166 100
Group 5 Prostate: Grade Post Therapy Answer N Percent
BLANK 142 85.5 9 21 12.7
4 2 1.2
5 1 0.6
Total 166 100
Group 5 Prostate: PSA Lab Value Answer N Percent
646.0 139 83.7 647.0 14 8.4
64.6 2 1.2
646.9 2 1.2
15.4 1 0.6
22.0 1 0.6
464.0 1 0.6
600.0 1 0.6
601.0 1 0.6
616.0 1 0.6
64.0 1 0.6
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 151
Answer N Percent
650.0 1 0.6
98.0 1 0.6
Total 166 100
Group 5 Prostate: Gleason Patterns Clinical Answer N Percent
45 160 96.4 X9 3 1.8
43 1 0.6
54 1 0.6
X6 1 0.6
Total 166 100
Group 5 Prostate: Gleason Score Clinical Answer N Percent
09 160 96.4 05 3 1.8
X9 2 1.2
07 1 0.6
Total 166 100
Group 5 Prostate: Gleason Patterns Pathological
Answer N Percent
X7 140 84.3 X9 15 9
45 8 4.8
X6 2 1.2
X8 1 0.6
Total 166 100
Group 5 Prostate: Gleason Score Pathological Answer N Percent
X7 141 84.9 X9 14 8.4
09 7 4.2
05 2 1.2
07 1 0.6
X8 1 0.6
Total 166 100
Group 5 Prostate: Gleason Tertiary Pattern Answer N Percent
X7 116 69.9 30 41 24.7
X9 8 4.8
40 1 0.6
Total 166 100
Group 5 Prostate: Number of Cores Examined Answer N Percent
14 162 97.6 07 1 0.6
12 1 0.6
99 1 0.6
X9 1 0.6
Total 166 100
Group 5 Prostate: Number of Cores Positive Answer N Percent
14 162 97.6 06 1 0.6
07 1 0.6
99 1 0.6
X9 1 0.6
Total 166 100
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 152
Group 5-Soft Tissue Abdomen and Thoracic
Group 5 Soft Tissue: Primary Site Answer N Percent
C494 156 96.3 C474 3 1.9
C495 2 1.2
C169 1 0.6
Total 162 100
Group 5 Soft Tissue: Histology Answer N Percent
8832 155 95.7 8833 3 1.9
8000 1 0.6
8800 1 0.6
8823 1 0.6
9332 1 0.6
Total 162 100
Group 5 Soft Tissue: Behavior Answer N Percent
3 160 98.8 1 2 1.2
Total 162 100
Group 5 Soft Tissue: Tumor Size Clinical Answer N Percent
069 136 84 090 15 9.3
999 5 3.1
070 3 1.9
000 1 0.6
062 1 0.6
690 1 0.6
Total 162 100
Group 5 Soft Tissue: Tumor Size Pathologic Answer N Percent
100 135 83.3 010 10 6.2
999 6 3.7
052 3 1.9
069 3 1.9
989 3 1.9
000 1 0.6
030 1 0.6
Total 162 100
Group 5 Soft Tissue: EOD Primary Tumor Answer N Percent
100 150 92.6 999 4 2.5
200 3 1.9
400 2 1.2
550 2 1.2
300 1 0.6
Total 162 100
Group 5 Soft Tissue: EOD Regional Nodes Answer N Percent
000 137 84.6 999 23 14.2
800 2 1.2
Total 162 100
Group 5 Soft Tissue: Regional Nodes Positive Answer N Percent
98 130 80.2 00 20 12.3
99 11 6.8
88 1 0.6
Total 162 100
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 153
Group 5 Soft Tissue: EOD Mets Answer N Percent
00 160 98.8 99 2 1.2
Total 162 100
Group 5 Soft Tissue: SS2018 Answer N Percent
1 152 93.8 2 5 3.1
9 4 2.5
4 1 0.6
Total 162 100
Group 5 Soft Tissue: Grade Clinical Answer N Percent
9 155 95.7 1 3 1.9
A 3 1.9
B 1 0.6
Total 162 100
Group 5 Soft Tissue: Grade Pathological Answer N Percent
9 135 83.3 A 9 5.6
B 8 4.9
1 6 3.7
2 2 1.2
C 2 1.2
Total 162 100
Group 5 Soft Tissue: Grade Post Therapy Answer N Percent
BLANK 143 88.3 9 19 11.7
Total 162 100
Group 5 Soft Tissue: Bone Invasion Answer N Percent
0 152 93.8 9 10 6.2
Total 162 100
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 154
Group 5-Tongue Anterior
Group 5 Tongue Anterior: Primary Site Answer N Percent
C022 135 83.9 C028 16 9.9
C029 6 3.7
C020 2 1.2
C023 2 1.2
Total 161 100
Group 5 Tongue Anterior: Histology Answer N Percent
8071 95 59 8070 60 37.3
8020 1 0.6
8041 1 0.6
8052 1 0.6
8086 1 0.6
8170 1 0.6
8171 1 0.6
Total 161 100
Group 5 Tongue Anterior: Behavior Answer N Percent
3 161 100 Total 161 100
Group 5 Tongue Anterior: Tumor Size Clinical Answer N Percent
999 157 97.5 030 3 1.9
000 1 0.6
Total 161 100
Group 5 Tongue Anterior: Tumor Size Pathologic
Answer N Percent
3 161 100 Total 161 100
Group 5 Tongue Anterior: EOD Primary Tumor Answer N Percent
200 80 49.7 500 48 29.8
100 13 8.1
650 11 6.8
300 4 2.5
000 2 1.2
400 2 1.2
150 1 0.6
Total 161 100
Group 5 Tongue Anterior: EOD Regional Nodes Answer N Percent
000 159 98.8 800 2 1.2
Total 161 100
Group 5 Tongue Anterior: Regional Nodes Positive
Answer N Percent
00 161 100 Total 161 100
Group 5 Tongue Anterior: EOD Mets Answer N Percent
00 161 100 Total 161 100
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 155
Group 5 Tongue Anterior: SS2018 Answer N Percent
1 105 65.2 2 43 26.7
7 9 5.6
0 3 1.9
9 1 0.6
Total 161 100
Group 5 Tongue Anterior: Grade Clinical Answer N Percent
9 151 93.8 1 7 4.3
2 2 1.2
3 1 0.6
Total 161 100
Group 5 Tongue Anterior: Grade Pathological Answer N Percent
1 150 93.2 9 9 5.6
2 2 1.2
Total 161 100
Group 5 Tongue Anterior: Grade Post Therapy Answer N Percent
BLANK 142 88.2 9 17 10.6
1 1 0.6
2 1 0.6
Total 161 100
Group 5 Tongue Anterior: Extranodal Exten H&N Clin
Answer N Percent 7 61 37.9 9 51 31.7
0 42 26.1
1 6 3.7
8 1 0.6
Total 161 100
Group 5 Tongue Anterior: Extranodal Exten H&N Path
Answer N Percent
X.7 141 87.6 0.0 11 6.8
X.9 7 4.3
0.9 1 0.6
X.8 1 0.6
Total 161 100
Group 5 Tongue Anterior: LN Size Answer N Percent
0.0 149 92.5 XX.9 4 2.5
00.0 1 0.6
1.0 1 0.6
1.7 1 0.6
2.1 1 0.6
24.0 1 0.6
9.9 1 0.6
XX.4 1 0.6
XX.8 1 0.6
Total 161 100
Appendix 4: 2019 EOD/SS/SSDI.Reliability Study. Answer Distribution
February 4, 2020 Appendix 4 P a g e | 156
Group 5 Tongue Anterior: SEER SSF: Human Papilloma Virus (HPV) Status
Answer N Percent
9 155 96.3 0 6 3.7
Total 161 100
